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ABSTRACT 
Heme is vital to a variety of cellular functions in bacteria ranging from energy generation 
to iron reserve. Group A streptococcus (GAS) is a prevalent bacterial pathogen that is 
responsible for an array of human diseases ranging from simple, self-limiting, mucosal and skin 
infections to invasive and systemic manifestations. GAS needs iron for growth and can satisfy 
this nutritional requirement by scavenging the metal from heme. The pathogen produces 
powerful hemolysins that facilitate heme release during infection. Heme is captured and relayed 
through the GAS cell wall and cytoplasmic membrane by dedicated receptors and transporters. 
To-date, the fate of the acquired heme is unknown in Streptococci. Although heme is 
nutritionally beneficial for GAS growth, its pro-oxidant and lipophilic nature makes it a liability 
 
 
with damaging effects on cellular components. The conundrum associated with heme use is 
particularly pertinent to GAS pathophysiology since invasive GAS infections involve massive 
hemolysis and the generation of unescorted heme in excess. In this dissertation, I aimed to 
describe the mechanisms that GAS uses for heme catabolism while managing its toxicity. I 
conducted a biochemical characterization of a new enzyme, HupZ in GAS that degrades heme in 
vitro. Similar to the heme oxygenase-1 (HO-1), HupZ activity leads to the formation of iron, CO, 
and a biliverdin-like product. I also investigated the impact of heme on GAS physiology and 
identified key mediators in the repair and detoxification process. This study demonstrated that 
heme exposure leads to a general stress response that involves the activation of antioxidant 
defense pathways to restore redox balance. Further, I studied a 3-gene cluster, pefRCD 
(porphyrin-regulated efflux RCD), which was activated by environmental heme, and provided 
support to my hypothesis that the pefRCD gene encodes a heme-sensing regulator (PefR) and 
heme efflux system (PefCD). I showed that the pef system protects GAS cells from heme-
induced damage to the membrane and DNA by preventing cellular accumulation of heme. In 
conclusion, this dissertation addresses key knowledge gaps in GAS physiology and provides new 
insights into heme metabolism of GAS.  
 
 
 
 
 
INDEX WORDS: Heme tolerance, Group A streptococcus, Gram-positive, heme sensing, 
mutational analysis, heme toxicity, heme tolerance, PefRCD transporter, heme efflux, 
heme degradation, HupZ protein, UV-vis spectroscopy, iron and CO release.  
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1 GENERAL INTRODUCTION 
1.1 Group A streptococcus 
Group A streptococcus (GAS) also commonly known as Streptococcus pyogenes is a Gram-
positive, beta-hemolytic, obligate human pathogen that can adapt and flourish in numerous micro 
environments within the human body. GAS infections are realized in a range of manifestations 
from superficial, self-limiting infections of the mucous membranes and skin (pharyngitis, 
pyoderma, impetigo, etc.) to more severe and rare invasive infections (bacteremia, necrotizing 
fasciitis, streptococcal toxic shock syndrome, etc.) (1, 2). In certain patients GAS can cause 
autoimmune complications in the form of glomerulonephritis or acute rheumatic fever (3, 4). 
Occurrences of rheumatic fever is linked to rheumatic heart disease and neurological 
complications (5).  
 
1.2 GAS burden. 
GAS infections are ranked among the top 10 causes of infectious mortality (1). Worldwide, GAS 
causes ~700 million infections every year of which 1.8 million are invasive manifestations with 
25% mortality rate (~450,000 patients succumb to death) (6). The non-invasive infections are 
treated with the β-lactam group of antibiotics; however, the invasive manifestations of GAS are 
rapid, aggressive, and difficult to manage. Often surgical amputation is the only available 
alternative that significantly impairs the lifestyle of the patients and requires extensive care (7). 
Manifestations of acute-rheumatic fever following GAS pharyngeal infections cause damage to 
joints and heart and account for a significant morbidity (~223,000 cases worldwide) (3, 4). In the 
absence of efficacious and licensed vaccines made for human practices, the understanding of the 
GAS-host interactions is an important strategy that may facilitate the design of novel therapeutics 
for combating GAS infections (8).  
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1.3 GAS virulence 
The pathophysiology of GAS is very complex; GAS is a versatile pathogens that is armed with 
more than 50 identified virulence factors, some are shared by all strains (consisting of the core 
virulon) while others are strain-specific. GAS virulence factors contribute to the different stages 
of infection and pathologies, occasionally serving redundant functions. The highlights of some of 
GAS core virulence factors are as follows: 
M protein: The M protein is the major surface and virulence determinant in GAS, it protects the 
bacterium from phagocytosis and facilitates adherence to the host epithelium (2). The cell wall 
anchored M protein is encoded by the emm gene. The hyper variability of M protein is the basis 
for GAS serotyping. There are more than 200 M protein types identified in GAS up to date (6). 
Capsule: GAS produces hyaluronic acid capsule that coats the bacterial cell and protects it from 
complement deposition and phagocytosis (9-11). Capsule biosynthesis in GAS is brought about 
by the hasABC operon, which codes for membrane bound synthase leading to the assembly of a 
linear hyaluronic acid polymer made out of alternating units of glucuronic acid β-1,-3 linked to 
N-acetylglucosamine (12, 13). The capsular gene expression is increased during GAS growth in 
blood  
Cytolysins: GAS cells produces two hemolysins, SLO and SLS. SLO is an oxygen-labile, 
cholesterol-dependent toxin that is produced throughout the exponential phase of growth (14). 
The SLO protein oligomerizes in the membrane of the host cells, creating large pores (25-30 nm) 
and leading to cellular damage and activation of apoptotic pathways (15). SLS, which consists of 
a peptide, is an oxygen stable toxin used by GAS to resist immune killing. This toxin can create 
hydrophilic pores in the neutrophils membrane. SLS biosynthesis and export is encoded by the 
sagA-I operon, which is expressed during the stationary phase of growth (16, 17). 
SpeB: The Streptococcal pyrogenic exotoxin B is a cysteine protease secreted by GAS cells from 
the late exponential to stationary phase (18, 19). In the activated form, the SpeB zymogen aids in 
immunoglobulin degradation and the establishment of GAS in skin and soft tissue niches (20-22).  
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Peptidases: The C5a peptidase called ScpA is a serine protease that cleaves C5a chemoattractant.  
The ScpA protein prevents the recruitment of neutrophils to the site of infection and the 
generation of the peroxide burst associated with the phagocytosis process occurring subsequent to 
neutrophil infiltration (23, 24). ScpC is another cell wall anchored peptidase, which inactivates 
cytokines (e.g. interleukin-8) and impairs the recruitment of neutrophils (25). 
Streptodornases (deoxyribonucleases): The neutrophil extracellular traps (NET) are excessive 
extracellular DNA network produced by neutrophils. The NET captures bacteria and facilitates 
their killing using the antimicrobial effectors associated with it and enables bacterial detection by 
the cells of the immune system. GAS produce and secret two DNases, Sda1 and Sda2, which act 
to dissolve the NET and thus prevent subsequent detection (by TLR9) and clearance (26, 27). 
 
In addition to the virulence factors described above, GAS secretes a number of proteins capable 
of modifying the host molecules and tissues and help in the pathogen dissemination and/or 
subversion of the host immune response. For example the streptokinase (Ska) protein is a 
plasminogen activator secreted by GAS during invasive infections. Ska converts the host 
plasminogen to the active protease, plasmin. Plasmin is then recruited and used by GAS to 
dissolve the host extracellular matrix (ECM) and facilitates the bacterial spread (28).  
 
Like the majority of pathogens, GAS requires iron for growth and this elemental requirement is 
linked to the virulence potential of GAS (29-31). During infections heme and hemoproteins serve 
as a largest reserve for metal iron. GAS is endowed with a number of molecular mechanisms to 
acquire iron from the host heme (and or hemoproteins) (30, 32, 33). In this respect, heme 
metabolism is central for the survival and success of GAS as a human pathogen; yet significant 
knowledge gaps regarding this aspect in GAS physiology exist. 
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1.4 Dissertation objectives and significance 
The purpose of this dissertation is to describe the mechanisms for heme homeostasis in GAS. In 
chapter 1, I laid the theoretical foundation for my studies by providing a review on the current 
understanding of heme, its juxtaposing nature and interactions in bacterial systems. In chapter 2, I 
addressed the fate of the intracellular heme in GAS by characterizing a new enzyme, named heme 
utilization protein Z (HupZ). Dr. Mahamoudou Ouattara, a former member and colleague in Dr. 
Eichenbaum’s lab, cloned and begun describing this enzyme. I devoted my efforts in 1) 
optimizing the heme degradation process, 2) identifying the products of heme catabolism and 3) 
conducting in-silico analysis to establish the phylogenetic placement of HupZ. The elucidation of 
heme biotransformation by HupZ could serve as a novel pathway for heme catalysis in 
streptococcal pathogens. Successful mammalian infections involve evasion of the host defenses, 
here streptococcus is exposed to highly oxidative environment and reactive species (34). In 
addition, as a hemolytic pathogen that spreads through the blood, GAS is likely to encounter toxic 
levels of heme during infection. In Chapter 3, I described the impact of environmental heme on 
GAS physiology. I illustrated the toxic implications of environmental heme, characterized GAS 
response to heme stress, and identified GAS mechanisms for heme tolerance. In Chapter 4, I 
aimed to describe the function of a new pathway, named pefRCD (porphyrin-regulated efflux 
RCD) and its contribution to heme tolerance in GAS. This investigation revealed that the PefCD 
protein consists of an ABC-type transporter that exports heme and defends GAS cellular 
components from heme damage. Together, this dissertation provides new insights into heme 
metabolism in GAS and in Streptococcus overall. Because of the importance of these new 
pathways to streptococcal biology and interactions of GAS with its human hosts, they consist of 
potential targets for new therapeutic modalities against streptococcal infections. 
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2 CHAPTER 1. THE CORNUCOPIAS INTERACTIONS OF PORPHYRIN-
HEME IN A BACTERIAL SYSTEM   
 
 
Summary for mini-review: There is a significant portion of research dedicated to heme 
acquisition, uptake, and utilization in bacteria. However, the important part that heme 
plays in the production of redox stress and cellular damage in bacterial systems is less 
understood. The purpose of this mini-review is to provide insights into heme metabolism 
in bacteria. This paper is centered on the biochemical attributes of heme, heme 
interactions that lead to toxicity, and the bacterial mechanisms for heme tolerance. A 
special focus is given in this review to the group A streptococcus (GAS).  
 
2.1 Iron, heme, and infection in mammalian systems.  
Iron, the first-row transition metal, participated early in the evolution of life and to date 
remains an essential element for the vast majority of organisms including bacteria. The 
human body, for example, contains about 3-4 grams (gm) of iron. However, under 
normal physiological conditions, iron that partitions within mammalian system is not 
readily available (35, 36). Mammals have evolved multiple ways of sequestering iron in 
both the extracellular and the cellular compartments not only to keep it soluble and 
transferable but also to prevent the toxicity that is associated with the free metal. In 
addition, since the majority of bacteria require about 10-6 to 10-7 M of iron for growth (37, 
38), iron withholding also serves as a form of nutritional immunity in response to 
infection.  
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The extracellular fluids in the body are rich with oxygen and have a neutral pH. Under 
these conditions, the iron is in the ferric form, which is extremely insoluble and therefore 
must be bound to carrier proteins. The hepatic glycoproteins, transferrin and lactoferrin, 
transport the ferric iron in the blood and body secretions (e.g. milk, tears, sweat, nasal 
secretion, and saliva) respectively. The low solubility and the high binding affinity of 
ferric iron to transferrin and lactoferrin (association constant of about 1036) leave the 
interstitial fluids with an extremely low concentration of free metal [10-18 M] (39). 
Transferrin-iron complexes circulate in the blood (with only 20-45% of transferrin 
binding sites being filled) and the iron is eventually delivered to various cells by binding 
to the transferrin receptors and subsequent endocytosis of the receptor-transferrin 
complexes. In the intracellular compartment, most of the inorganic iron is stored in the 
protein ferritin, which is mostly found in the cells of the liver and heart. It is heme 
however, that represents the largest reserve of iron in the body (~80%). In the heme 
molecule, the iron is coordinated by protoporphyrin IX (PPIX) that serves to solubilize 
the metal and increases its catalytic activity by several folds (40). The majority of the 
heme in the body is bound in hemoglobin and myoglobin, and found in erythrocytes and 
muscle tissues (41). When heme and/or hemoglobin are released to the extracellular 
compartment due to the lysis of erythrocytes or of other cells, heme components are 
quickly bound by the carrier proteins hemopexin and heptoglobin and transported to the 
liver for recycling.  
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The daily iron requirements in humans are about 20-23 milligrams (mg). On average, 
only 1–2 mg of dietary iron is absorbed daily. The recycling of iron reserves generally 
from aging erythrocytes accounts for the rest of the metal iron (Figure 1). Iron recovery 
from hemoglobin in senescent erythrocytes occurs in the macrophages of the lymphoid 
tissues. A transporter named ferroportin mediates the export of iron from cells (such as 
macrophages and the intestinal enterocytes) into circulation. Hepcidin, a peptide hormone 
secreted by the liver, controls this process and therefore manages the overall extracellular 
availability of iron (42, 43). Hepcidin functions by binding to ferroportin and causing its 
eventual degradation.  
 
In response to signals generated during infection processes, the liver secrets elevated 
amounts of hepcindin, which in turn acts to reduce the export of cellular iron into 
circulation. The liver also releases more hemopexin, heptoglobin to sequester heme and 
hemoglobin from the serum. In addition, apo-lactoferrin is secreted by neutrophils and 
macrophages are induced to enhance their uptake of iron and its further storage within 
ferritin (44). Collectively, this response leads to hypoferremia, further reducing the 
availability of iron at the extracellular compartment. 
 
2.2 Heme.  
Porphyrins (literal translation of Greek word porphura refers to the color “purple”) are a 
universal class of heterocyclic compounds that support a myriad of biological processes. 
The chemical composition of porphyrins can be best described as an aromatic, 16 carbon 
atom ring scaffold which contains 4 nitrogen atoms obtained by the linking of 4 
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tetrapyrrolic subunits with 4 methine bridges. This marcrocycle, utilizes inwards facing 
nitrogen atoms to coordinate various metal ions forming secure metalloprophyrins 
(Figure 2) (45). The stable complexes between transition metals cations and porphyrins 
are attributed to the aromaticity of the heterocyclic compound. It is the porphyrin portion 
that accounts for the increased solubility and catalytic activity in the biological systems 
for the metal component. The high stability of the porphyrins with transition metals is 
exemplified by Zn-tetraphenylporphyrin (ZnTPP), which has a stability constant of 1029 
(46, 47). Iron-porphyrins (heme) are known for their redox reactions. Heme and heme-
proteins have versatile biological functions including serving as sensors and transporters 
of diatomic gases, biotransformation and detoxification of metabolites, chemical catalysis 
(serving as a ‘source’ or ‘sink’ of electrons in redox reactions), and an important iron 
reserve on which invading pathogen often rely (48). 
 
The photoactive nature of porphyrin makes it a highly useful target in spectroscopy. The 
chief characteristic absorption peak of protoporphyrins is around 380-400 nm (Figure 3). 
This peak, known as the Soret or B-band, arises due to fully conjugated aromatic π-
system that allows transition from the ground state to a second excited state. The Q bands 
are weaker absorbance peaks that occur after the Soret band. This region consists of a 
weak transition of electrons to the first excited state and ranges between 500-750 nm 
(49). Protonation of the inner nitrogen atoms of protoporphyrins, which occurs during 
insertion of metal ions, causes strong changes in the visible absorption spectrum. Minor 
variations in absorption spectrum can take place due to distal substituents. In addition, the 
absorbance maxima are greatly influenced by the electronic state of iron, interactions 
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with small ligands, and contact with amino acid side chains in the heme-binding pocket 
or with axial ligands in a protein-bound heme. Figure 3 illustrates the various absorbance 
spectra of free PPIX and heme as well as heme bound to the PefR protein of group A 
Streptococcus. Holo-PefR depicts Soret absorbance between 404-430 nm and β, α bands 
of heme absorb between 500-600 nm (50). Spectroscopic analysis provides a powerful 
tool in analyzing the function of proteins and enzymes that use heme as a prostatic group 
or cofactor. The ability to depict and monitor spectral behaviors has facilitated studies of 
diverse reactions including heme binding, transfer, and degradation that have enhanced 
our understanding of protein structures and functions.  
 
2.3 Heme uptake.  
With only few exceptions (e.g. Borrelia burgdorferi and some Lactococcal species), iron 
is an indispensible micronutrient for all organisms. Successful colonization, therefore, 
demands from invading bacteria to have means to obtain the nutrient iron from the host 
environments. Consequently, bacterial pathogens often obtain iron from heme and have 
evolved mechanisms to capture heme during infection. Gram-negative bacteria deploy 
secreted hemophores or outer membrane receptors that can capture free heme or scavenge 
it from host hemoproteins (such as hemoglobin and hemopexins). In both mechanisms, 
the heme is delivered through the outer membrane and into the periplasmic space by Ton-
dependent receptors using the proton motive force of the cytoplasmic membrane to 
energize this process (51, 52). Hemophore-mediated uptake of heme for pathogenic 
bacteria such as Pseudomonas aeruginosa, Yersinia pestis, and Hemophilus influenza has 
been demonstrated (53-55). The outer-membrane receptors HmbR and HpuA of Neisseria 
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species and HutA of Vibrio Cholerae were shown to capture heme directly from host 
proteins (56-58). In the periplasmic compartment, heme is captured by heme-binding 
proteins and delivered across the inner membrane via dedicated ABC transporters, using 
ATP hydrolysis to support the transport process.  
 
Like Gram-negative bacteria, Gram-positive organisms also employ secreted hemophores 
or dedicated surface receptors to capture heme from the extracellular milieu or to seize it 
from the host hemoproteins. Nevertheless, significant differences in the nature of this 
process and acquisition machinery exist, reflecting the differences in the cell envelope of 
Gram-negative and Gram-positive organisms. Gram-positive bacteria are missing the 
selective barrier provided by the outer membrane. On the other hand, the delivery of 
heme to the cytoplasmic membrane has to overcome the challenge imposed by the thick 
and dense Gram-positive peptidoglycan cell wall. A common approach that evolved 
among Gram-positive organisms is the use of a protein relay apparatus that facilitates 
heme shuttling from secreted hemophores or surface exposed receptors through the 
peptidoglycan layers to heme-binding proteins in the cytoplasmic membrane. Not 
surprisingly, the ABC-type transporters involved in this process are homologous to those 
used by Gram-negative bacteria to mediate the transport through the cytoplasmic 
membrane.  
 
A few heme-capture and relay mechanisms have evolved independently among Gram-
positive organisms. The best understood machinery, named Isd (iron-regulated surface 
determinant), was first described in Staphylococcus aureus. Orthologous systems have 
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been recognized in a number of pathogens including Bacillus anthracis, Bacillus cereus, 
and Listeria monocytogenes (59). Heme uptake by Isd-like proteins, involves a protein 
module named NEAT (NEAr-iron Transporter), which is carried in one or more copies 
by the Isd and Isd-like proteins. After it is captured by a NEAT domain belonging to 
surface exposed Isd proteins, heme is relayed to the downstream NEAT domains of 
proteins located deeper in the cell wall, until it reaches the cytoplasmic membrane (41, 
60, 61). While in most cases, the Isd proteins are anchored to the cell wall; Bacillus 
anthracis also employs NEAT-based hemophores, IsdX1 and X2, to capture labile heme 
(61, 62). NEAT independent mechanisms of heme relay were described in 
Corynebacterium diphtheriae (63) and Mycobacterium tuberculosis. However, the 
molecular bases for the function of these receptors are not fully understood. 
 
The major heme uptake pathway in GAS is named the streptococcal iron acquisition (sia) 
system. The Sia machinery consists of 10-gene operon whose expression is directly 
repressed by an iron and manganese-dependent repressor named MtsR (64, 65). The 
streptococcal hemoprotein receptor (Shr) captures heme from hemoglobin via its NEAT 
domains and transports it to the NEAT-like domain of the streptococcal hemoprotein 
(Shp), which further delivers it to the binding protein SiaA (31, 33, 66). Other than the 
presence of NEAT and NEAT like domains, Shr and Shp do not share homology to Isd 
proteins, and unlike most Isd proteins they are anchored in the cell membrane instead of 
the cell wall. The transport of heme through the cytoplasmic membrane is completed by 
the membrane permease and ATPase encoded by the siaB and siaC genes respectively. A 
second ABC transporter named streptococcal iron uptake system (siuABC) contributes to 
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GAS growth in iron-depleted medium supplemented with whole blood or hemoglobin 
(30). However, heme binding or transport by the SiuABC was not directly demonstrated. 
 
2.4 Heme degradation.  
The recycling of iron from heme typically necessitates heme catalysis, which involves 
oxidative cleavage by heme oxygenases (HOs). In addition to HOs being key components 
in heme catabolism and iron homeostasis, these enzymes are associated with oxidative 
stress management, the synthesis of light harvesting pigments phytobilin in plants, algae, 
and cyanobacteria, and represent important iron acquisition pathways in bacterial 
pathogens (67). The majority of the bacterial HOs are homologous to the mammalian 
HO-1 enzyme. HO utilizes oxygen dependent reactions to cleave heme and generate 
equimolar amounts of biliverdin (BV) IX, iron, and carbon monoxide (CO). In this 
reaction heme acts as both substrate and a cofactor, and total of three oxygen molecules 
and seven electrons are consumed during this reaction. The reducing equivalents for 
heme catalysis are provided by NADPH (67).  
 
Depending on the position of the eliminated carbon in the heme precursor, heme cleavage 
can produce four possible isomers of BV, i.e. α, β, γ, and δ. In mammals and plants, HOs 
preferentially initiate degradation at α -meso carbon to yield BV IXα (68). Degradation of 
heme by HO is a multi-step process that in most cases proceeds with intermediates like 
hydroxyheme and verdoheme to yield BV. In mammals, BV is further reduced by 
biliverdin reductase (BVR) to yield bilirubin (BR) (Figure 4 and 5) (48). The productions 
of BV, BR, and CO contribute to cytoprotection and have been targeted for developing 
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therapeutics (69, 70). The fate and the purpose of BV that is generated during bacterial 
heme catalysis are largely unknown, except for cyanobacteria (71). In eukaryotes, most 
HOs use NADPH in conjunction with cytochrome P450-reductase (CPR) for the transfer 
of electrons from NADPH. CPR is a flavin containing enzyme that facilitates the flow of 
electrons from NADPH to FAD, from FAD to FMN, and finally from FMN to HO (and 
cytochrome P450) (72). Bacterial HOs can use CPR, Trolox, ascorbate, and or 
Ferrodoxin/Ferrodoxin reductase (for PigA, pa-HO, and BphO) as in vitro redox partners 
(67). The identity of the native redox partners is unknown for most bacterial HOs  [except 
for pigA of P. aeruginosa, which can use pa-FPR for electron transfer during heme 
catalysis (73)].  
 
The most extensively studied heme oxygenases are the human HO-1 and HO-2 enzymes. 
The gene encoding HO-1 is induced in response to iron limitations and other 
environmental cues in most tissues with the exception of the liver and spleen. HO-2 
expression is typically constitutive (48). As expected from enzymes involved in iron 
supply, the vast majority of bacterial HOs are induced during growth in low iron 
conditions. HO-1 is a large (~36 kDa) membrane bound protein. Most of the 
characterized HOs in bacteria (including HemO, PigA, HmuO) share homology to HO-1. 
These enzymes however, are missing the C-terminus anchor residues, and are therefore 
smaller (~13-25 kDa) and located in the cytosol (67). The bacterial HOs that do not share 
homology with the eukaryotic enzymes (such as ChuS from E. coli1 O157, IsdG/I from 
S. aureus, MhuD from M. tuberculosis) are considered non-canonical. IsdG and IsdI from 
S. aureus are examples from a non-canonical HO group that has a homodimeric β-barrel 
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fold with two active sites at the dimer interface. Holo-IsdG shows significant ruffling 
(non-planarity) of the bound heme leading to distortion in tetrapyrrole. Unlike most HOs, 
IsdG catalyzes the liberation of one of the meso-carbons as formaldehyde instead of CO. 
This reaction produces staphylobilin, an oxo-bilirubin chromophore rather than BV (74-
76). This unique chemistry implies not only different mechanism of oxygen activation 
but also a distinctive evolutionary path of IsdG and related enzymes such as IsdI. The HO 
of M. tuberculosis, MhuD, depicts heme-ruffling mechanism analogous to that of IsdG 
family. However, MhuD produces an unusual product termed mycobilin, in which the 
meso-carbon atom at the site of the ring cleavage remains attached as an aldehyde group 
(77).  
 
A new family of bacterial HOs with no sequence conservation to HO-1 was recently 
identified. These enzymes include ChuZ of C. jejuni, HutZ of V. Cholerae, and HugZ of 
H. pylori (78-80). Enzymes from this family have a putative FMN-like binding site with a 
split β-barrel fold of homodimers. However, actual flavin binding is yet to be confirmed. 
The non-canonical HOs are currently in the spotlight due to unusual heme coordination, 
and production of unusual products with varied regiospecificity. GAS is able to thrive in 
iron-restricted medium as long as it is supplemented with hemoglobin or other 
hemoproteins. Heme utilization by GAS is quite evident but the catabolic enzyme(s) 
remains to be identified. Notably, the GAS genome does not share homology to any of 
the known canonical or non-canonical HOs. 
 
2.5 The redox-active nature of heme.  
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The machinery for heme uptake and degradation can supply bacteria with the growth 
essential iron during infection. Paradoxically, this survival strategy can lead to cellular 
damage, and the toxicity may be augmented when high levels of heme are encountered at 
the infection site. The noxious effects of heme in bacteria are thought to be multifactorial. 
Heme iron can participate in redox reactions that can in turn induce oxidative stress. 
Oxidative stress occurs when the accumulation of free radicals exceeds the natural ability 
of an organism to protect itself from radical damage. Heme is able to catalyze the 
formation of reactive oxygen species (ROS) through multiple pathways (81). One of 
these pathways, known as the Fenton reaction, which occurs when either ferric or ferrous 
iron reacts with hydrogen peroxide (H2O2) to form hydroxyl radicals (OH) (82). This 
process, which is cyclic in nature, is not only damaging by itself but can also lead to 
initiation of vicious oxidative cascade due to interactions between the radical species and 
various biomolecules. In humans, prolonged time spent in oxidative stress is related to a 
multitude of disorders caused by damage to membrane lipids and proteins as well as 
deficiencies in cellular signaling (83, 84). Studies have shown that hemin, the oxidized 
version of heme, is cytotoxic due to its ability to aggregate in cell membranes and trigger 
cell death (83). GAS showed heme-induced damages to membrane proteins, lipid 
components, and chromosomes [(50), Eichenbaum unpublished data]. The prevention and 
detoxification of heme stress is not well understood in most bacterial species. including 
GAS. 
 
2.6 Heme tolerance.  
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Heme degradation carried by HO seems to be an obvious defense choice for bacteria. 
(85). Sequestration of heme could be protective as well. In the Plasmodium parasite, free 
heme is removed by the heme detoxification protein (HDP), which forms an innocuous 
crystalized product called hemozoin (86). Sequestration of free iron by ferritin-like 
proteins is quite common among bacterial species (63). In addition, various cytoplasmic 
heme-binding proteins, such as HemS in Y. enterocolitica, function as interim heme 
chelating agents before shuttling it to a dedicated HO for breakdown (87). Proteins 
homologous to HemS that contribute to heme withholding and trafficking have been 
described in other Gram-negative bacteria. These include the ShuS protein of Shigella 
and the PhuS protein of Pseudomonas (88, 89). Active efflux is very useful in providing 
protection from heme toxicity in mammalian systems. Transporters that pump a single 
substrate (or a family of compounds) are considered dedicated transporters. Other 
systems, which exhibit more promiscuous nature and are able to extrude structurally 
distinct compounds, are referred to as multidrug resistance (MDR) efflux systems (90). It 
is not uncommon for an MDR transporter to detoxify heme; for example the mammalian 
feline leukemic viral receptor (FLCVR) and ABCG2 transporters confer heme tolerance 
in erythroid cells by conducting the export of heme excess out of hepatocytes and 
enterocytes in the gut lining (91). The MRP-5/ABCC5 MDR, which is known for 
removing the monophosphate metabolites of fluorinated pyrimidine compounds in 
metazoans is also essential in maintaining systemic heme homeostasis and in alleviation 
of heme stress (92). For the majority of MDR transporters, ion motive force (H+ or Na+) 
drives the pumping mechanism, but there are increasing evidences for reliance on ATP 
hydrolysis in heme efflux as well (93).  
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Among bacterial systems, S. aureus, group B streptococcus (GBS), and B. anthracis 
combat heme toxicity by export. These pathogens encode the heme-regulated 
transporter, HrtAB, which pumps heme (at levels of 1-10 M) and or toxic by-products 
of heme catabolism (94, 95). The regulatory network that controls heme tolerance in 
bacteria varies among different species. For example, the expression of the hrtAB genes 
in the pathogenic S. aureus, B. anthracis, and C. diphtheria is responsive to the two-
components, HssSR, system. The non-pathogenic L. lactis, utilizes HrtR, a TetR family 
of regulator in heme hemostasis (96). In addition to putative hrtAB genes, the 
opportunistic GBS employ a five-gene regulon that is referred to as ‘porphyrin-regulated 
efflux (pef) in managing the intracellular pools of heme and PPIX (95). A MarR-like 
protein, named PefR, repressed the pef regulon in a heme dependent manner. PefR 
disengages from its cognate operator sites upon binding to heme or PPIX. The pef 
regulon is expressed in response to lower levels of heme (0.1-10 M) than the putative 
hrtAB genes (10 M), and is thus proposed to function in the fine-tuning of intracellular 
heme levels. Knockout strains of hrtAB and pef systems are ultrasensitive to heme 
exposure, an observation that highlights a critical and an intricate regulatory mechanism 
for heme tolerance in pathogenic strains (95). Exporters from the general multiple 
transferable-resistance (mtr) family were also implicated in providing protection from 
heme stress in S. aureus and GBS (97).  
 
In GAS, we have recently shown that the transcription of a pefRCD-like operon is 
induced in response to environmental heme and demonstrate that the putative repressor, 
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PefR, specifically binds heme and PPIX in-vitro. In-silico analyses revealed a high 
degree of conservation of the Pef proteins among the 20 GAS genomes that are available 
in the database. In addition, the genomic organization of the pef locus is conserved 
among the streptococci from the pyogenic cluster (S. pyogenes, S. agalactiae, S. iniae, 
and S. equi). In vivo data collected with strains defective in functional pefCD genes 
illustrated an increased sensitivity to heme and anthracyclic compounds. Additionally, the 
lack of the PefCD proteins in GAS leads to increased heme-induced damage in lipids and 
DNA (Eichenbaum unpublished data, chapter 4). Thus, the pef system is the first type of 
efflux system linked to heme tolerance in GAS. Now, that we have established that labile 
heme causes cellular mayhem in GAS and GAS employs activation of protective 
pathways including pef system; it would be noteworthy to examine the mechanisms of 
pathogen heme-sensing and tolerance used during host infections. 
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3 CHAPTER 2- IN VITRO HEME BIOTRANSFORMATION BY THE HUPZ 
ENZYME FROM GROUP A STREPTOCOCCUS 
3.1 Introduction 
Most of the iron in mammals is bound to protoporphyrin IX in heme molecules, which 
are found in complex with hemoglobin, myoglobin, and other proteins. Pathogenic 
bacteria often tap into the heme reservoir to overcome the severe iron scarcity, which 
they encounter during infection. These pathogens use elaborate systems to scavenge 
heme from host hemoproteins and transport it into the bacterial cell (41, 98-100). A few 
mechanisms allow bacteria to retrieve iron from heme. For example, the release of iron 
from heme without breaking the macrocyclic ring by enzymes belonging to the family of 
dye-decolorizing heme peroxidases (DyP) has been described in Escherichia coli (101) 
and Staphylococcus aureus (102). The most common pathway, however, relies on 
oxidative cleavage of the porphyrin ring by enzymes known as heme oxygenases (HOs) 
(103, 104). When supplied with oxygen and electron donors, canonical HOs (e.g., HO-1 
in eukaryotes) break down heme through three sequential mono-oxygenation steps (105). 
In the first step, heme is reduced to the ferrous form and rapidly binds oxygen. A 
subsequent reduction and protonation generates ferric hydroperoxy species, which self-
hydroxylate the tetrapyrrole at one of the meso carbons forming a hydroxyheme 
derivative (-meso-hydroxyhemin). In the second step, the hydroxyheme reacts with 
another oxygen molecule and is converted to verdoheme with the release of a meso 
carbon as carbon monoxide (CO). In the third and rate-limiting step, the cyclic 
verdoheme is opened through a reaction with oxygen, producing biliverdin and iron. Like 
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HO-1, many bacterial HOs specifically hydroxylate the porphyrin at the -meso carbon 
and eventually produce -biliverdin. Some bacterial enzymes however, demonstrate 
different regiospecificity and produce alternative or a mixture of biliverdin isomers (103, 
104). 
 
The first bacterial HO to be discovered was HmuO, a homologue of the human HO-1 
enzyme found in the pathogen Corynebacterium diphteriae (106, 107). Other HOs that 
also show significant structural and functional similarities to HO-1 were identified and 
characterized in several bacteria including Neisseria meningitidis (HemO) (108, 109), 
Clostridium species (HemO) (110, 111) and Pseudomonas aeruginosa, PigA (pa-HO or 
HemO), and BphO (112, 113). Like the mammalian enzymes, these bacterial HOs have a 
single compact domain that consists mostly of α-helices, with the heme inserted in 
between two of the α-helices (104). These bacterial enzymes degrade heme to α-
biliverdin, with the exception of PigA, which produces a mixture of β- and δ-biliverdin 
isomers (112-115). Most of the characterized HOs in bacteria are associated with iron 
acquisition and are negatively regulated by iron (41, 116). BphO, however, appears to be 
an exception as it is expressed independently of iron availability and serves only to 
produce the precursor for the phytochrome chromophore (113-115).  
 
Bacteria also use HOs that evolved independently of HO-1 like proteins; ChuS from E. 
coli O157:H7, for example, is such a non-conventional HO (117). ChuS has a unique 
structure that consists of two central sets of antiparallel β-strands, each flanked by two 
pairs of α-helices (117). Several cytoplasmic heme-binding proteins share sequence 
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homology with ChuS including HemS from Yersinia enterocolitica (87, 118), Bartonella 
henselae (119) and PhuS from P. aeruginosa (120). However, heme degradation was 
demonstrated only for a few family members (117, 119). In addition, it has been 
established that PhuS does not degrade heme and instead specifically delivers its heme to 
a partner HO (120, 121). Therefore, different proteins from this group may function in 
intracellular heme trafficking rather than in direct degradation of heme.  
 
IsdG from S. aureus is the prototype of a non-canonical HO group that has a distinctive 
homodimeric β-barrel fold with two separate active sites at the dimer interface (74, 122). 
IsdG catalyzes heme degradation by liberating one of the meso carbons as formaldehyde 
instead of CO; this reaction produces an oxo-bilirubin chromophore (staphylobilin) rather 
than biliverdin (123, 124). The unique catalytic mechanism of IsdG is attributed to the 
ruffling of the bound heme molecule and its impact on the chemistry of oxygen activation 
(123). S. aureus encodes two representatives of this family, IsdG and IsdI (74). Other 
members of the IsdG HO family include HmuD and HmuQ from Bradyrhizobium 
japonicum (125), IsdG homologues from Bacillus anthracis (75) and S. lugdunensis 
(126). MhuD from Mycobacterium tuberculosis is another HO related to IsdG with heme 
ruffling and which also degrades heme without CO release. However, MhuD produces a 
novel product named mycobilin, in which the meso-carbon atom at the site of the ring 
cleavage remains attached as an aldehyde group (77, 127). 
 
A new family of bacterial HOs with no homology to previously described enzymes was 
recently uncovered in Campylobacter jejuni (ChuZ) (78), Helicobacter pylori (HugZ) 
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(80, 128) and Vibrio cholerae (HutZ) (79, 129). Proteins from this family form 
homodimers with a split β-barrel fold that is characteristic of FMN-binding proteins, but 
no FMN binding was demonstrated. Interestingly, like PigA, HugZ exhibits δ-meso 
regiospecificity for cleaving the ring in the heme molecule (80), whereas HutZ is 
suggested to have β- or δ-meso regioselectivity (79). The exact nature of the bilin 
produced by HutZ or ChuZ reactions were not defined.  
 
The Group A Streptococcus (GAS) is a significant human pathogen that produces an 
array of clinical manifestations including infections of the mucosal membranes and the 
skin that are typically moderate, severe invasive infections, as well as post-infection 
sequelae (4, 130). GAS is a hemolytic bacterium that readily uses hemoglobin and other 
hemoproteins to satisfy its need for iron (131). A heme relay apparatus comprising Shr, 
Shp, and SiaABC (HtsABC) proteins mediates the capture and delivery of heme into 
GAS cell (32, 132-135). A second ABC transporter, SiuADBG, also contributes to heme 
acquisition in GAS through an unknown mechanism (30). Heme uptake is important for 
GAS pathogenesis and adaptation to the host environment. Accordingly, mutants in shr, 
sia or siu genes are attenuated for virulence (30, 31, 136). 
 
Despite the strides made in the field of heme uptake in Gram-positive bacteria, the 
mechanism for heme catabolism and iron release remains unknown in GAS and the 
Streptococcus genus. Herein, we provide biochemical evidences for in vitro heme 
binding and degradation by HupZ. Moreover, our structural and bioinformatics data on 
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HupZ, suggest that this streptococcal protein represents a new split β-barrel enzyme 
functioning in heme biotransformation.  
 
3.2 Materials and Methods 
 
3.2.1 Bacterial strains, media and antibiotics 
E. coli cells were grown aerobically, in Luria–Bertani (LB) medium at 37 °C 
supplemented with 100 µg/ml of ampicillin. In certain experiments cells were grown in 
the presence of 25 µg/ml of 5-aminolevulinic acid and 25 µg/ml of ferrous sulfate at 37 
°C under shaking conditions. The E. coli strains used in this study are listed in Table 1. 
 
3.2.2 Recombinant HupZ  
The hupZ gene was amplified from GAS using the pair of primers, ZE437-
ATGATAACACAAGAAATGAAA / ZE438- GTTACTTTCACTGTTTATTTCTT. The 
plasmids used in this study are listed in Table 1. The construction of HupZ-His 
expression vectors was accomplished by TOPO® directional cloning according to the 
manufacturer instruction (Invitrogen, K101-01). The hupZ gene was amplified from GAS 
NZ131 chromosome using the ZE437/ZE438 primer set and introduced into the 
pET101/D-TOPO vector. The resulting plasmid, pZZ2, codes for a HupZ-His tag fusion 
protein expressed from the T7 RNA polymerase promoter.  
 
3.2.3 Protein expression and purification 
Expression of the recombinant His-tagged proteins was induced overnight at 27 °C (or 5 
hours at 37 °C) with 1 mM isopropyl β-D-1-thiogalactopyranoside. Cells were harvested 
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and re-suspended in an extraction buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% 
Triton X-100) with the addition of 0.5 mg/mL Complete, mini-EDTA-free protease 
inhibitor cocktail tablets (Roche), then lysed by sonication. The cells’ pellet was 
centrifuged and the cleared lysate was then applied to a 5 mL HisTrap HP affinity 
column (nickel column) and purified using a FPLC. Purified protein was dialyzed in 
sodium phosphate buffer (SPB, 20 mM sodium phosphate, 500 mM NaCl, pH 7.4) prior 
to its use for experiments. Western blot analysis of the recombinant His-tagged protein 
was carried out using anti-His antibodies from mouse (Sigma). 
 
3.2.4 Heme reconstitution 
Heme reconstitution experiments were conducted as described in (134). Hemin chloride, 
the oxidized form of heme, was used in all experiments. For simplicity, in this manuscript 
we refer to iron-protoporphyrin complex in both redox states as heme. 
 
3.2.5 Heme degradation assays 
Heme-HupZ complex was prepared at a heme:protein ratio of 1.5:1 and excess heme was 
removed by filtration through a PD-10 column (GE Healthcare). Degradation of bound 
heme by HupZ was carried in the presence of NADPH [with NADPH regeneration 
system for heme degradation (Figure 7B) and iron release (Figure 9) or without 
regeneration system for heme degradation (Figure 7A) and the detection of CO (Figure 
8)] and human NADPH-cytochrome P450 reductase (CPR) or ascorbic acid. Ascorbic 
acid was added to a final concentration of 20 mM. In the NADPH-CPR system, heme-
HupZ protein (20 µM) was added to 0.4 μM of recombinant CPR. The reaction was 
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initiated by adding 100 μM of NADPH to the system and spectra were recorded from 250 
nm to 700 nm every 10 min for 1 h and every 60 min for additional 5 hours. Catalase 
(bovine liver, Sigma-Aldrich) was added to the reaction systems at a final concentration 
of 2 μM. The heme degradation reaction with ferredoxin reductase (FNR) and ferredoxin 
(Fdx) typically contained 20 M Holo-HupZ, 10 M Fdx, 0.1 unit/mL spinach FNR, 2 
M catalase and 500 M NADPH, in 1 mL SPB. The UV-visible absorption spectra were 
recoded before and at 10, 20, 30, 50 and 60 min after the addition of NADPH. 
 
3.2.6 Myoglobin differential spectroscopy 
5 M holoHupZ, 2 M catalase, 0.4 M CPR were mixed in 20 mM sodium phosphate 
buffer, pH 7.4, containing 500 mM NaCl. The reaction mixture was used as the blank and 
4 M of myoglobin solution was added immediately to the reaction. The UV-visible 
absorption spectrum of myoglobin was acquired over 16 min at 30 s intervals where 
reaction was initiated by the addition of 500 μM NADPH. The reference reaction was 
carried out similarly, except that instead of holoHupZ an equal volume of buffer was 
added, blanked, prior to adding 4 M of myoglobin and 500 μM NADPH. The reaction 
was carried out at 25 °C.   
 
3.2.7 Ferrozine differential spectroscopy 
20 M of holoHupZ, 2 M catalase, 200 M NADPH, 6.5 mM glucose-6-phosphate, 1 
unit/mL glucose-6-phosphate dehydrogenase, 0.4 M CPR and 1 mM ferrozine were 
mixed and the reaction was followed for several hours (spectra were recorded frequently 
for the first hour; then every 60 min for a total 5 hours. One time point was taken after 22 
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h). The reaction was carried out at 25 °C in a final volume of 750 L. The reaction was 
blanked with catalase, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, CPR 
and ferrozine in 50 mM MOPS buffer containing 500 mM NaCl (pH 7.4).   
 
3.2.8 Crystallization and data collection  
Crystals of HupZ were grown in hanging drops at room temperature by mixing 1 L of 
protein solution (6 mg/mL of protein) and 1 L of reservoir solution (20% PEG 3350, 0.2 
M lithium acetate). The crystals were cryo-cooled with a cryo-protectant containing 22% 
glycerol in addition to the mother liquor. The X-ray diffraction data were collected at 100 
K on beamline 22-ID of the Southeast Regional Collaborative Access Team (SER-CAT) 
at the Advance Photon Source, Argonne National Laboratory. The data were integrated 
and scaled with HKL2000 (137).  
 
3.2.9 Structure determination 
The crystal structure of HupZ was solved by molecular replacement employing PHASER 
(138, 139). The published structure of putative pyridoxamine 5-phosphate oxidase 
(PNPOx, PDB ID: 2HTD) sharing 28% sequence identity with HupZ was used as the 
initial model. Successful structure solution was obtained by pruning the N-terminal eight 
residues of the initial model and also using serine instead of the dissimilar amino acids in 
the HupZ sequence compared with the 2HTD sequence. The HupZ structure was 
constructed from the molecular replacement phases using the Arp/wArp program (140, 
141), which fitted 84% of the amino acid residues into the electron density. The model 
was subjected to several rounds of refinement in REFMAC (142) and the rest of the 
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protein structure was manually built with COOT (143). Solvent molecules were inserted 
at stereochemically reasonable positions using 2Fo-Fc and Fo-Fc maps at 1 and 3 sigma 
levels, respectively. The Rwork and Rfree values of the final refined structure are 17.0 % 
and 21.7 %, respectively. The data collection and refinement statistics are summarized in 
Table 2. The final refined structure has excellent protein geometry with no disallowed 
/ values on the Ramachandran plots. Structures were superimposed by secondary 
structure matching using SUPERPOSE (144) in CCP4 suite. The HupZ crystal structure 
was deposited with PDB ID 4NU4. 
 
3.3 Results 
3.3.1 HupZ is a new heme binding protein 
GAS growth in an iron-depleted medium is restored when the medium is supplemented 
with whole blood or various heme-containing proteins, indicating that the hemolytic 
pathogen can retrieve iron from heme (30, 32, 131, 134). Yet, bioinformatics analysis 
failed to locate homologs of characterized HOs in the GAS genome, suggesting that a 
new type of enzyme may be involved. In a recent microarray analysis we identified a 
putative gene (spy49_0662) that is repressed by MtsR, the global iron-dependent 
regulator of GAS (65). Spy49_0662 encodes a 15.9 kDa ORF containing the signature 
domain of PNPOx, found in FMN binding enzymes and evidently without any secretion 
signals. We therefore hypothesized that the iron-repressed spy49_0662 encodes a 
cytoplasmic enzyme involved in iron metabolism. 
To begin testing the function of Spy49_0662, we cloned and purified it from E. coli as a 
C-terminal end fusion to hexa-histidine tag. SDS-PAGE and Western blot examinations 
  
 
28 
revealed the presence of a single protein band that migrated to the expected size (Figure 
6A) and reacted with anti-His tag antibody (data not shown). UV-visible absorption 
spectrum of the purified protein did not exhibit significant absorption other than at 280 
nm (apo-HupZ, Figure 6B). However, when the HupZ was purified from cells grown in 
the presence of the heme precursors, 5-aminolevulinic acid and iron, it had a brown color 
and UV-visible scanning suggested that it was bound to heme (Figure 6C). To test if 
indeed heme serves as a ligand for Spy49_0662, we incubated it with heme (30 min at 
1:1.5 molar ratio, pH 7.4). After excess heme was removed, Spy49_0662 demonstrated 
absorption peaks at 414, 530, and 560 nm characteristic of a heme-bound protein (Heme-
HupZ, Figure 6B). The absorption maximum at the Soret region (390-430 nm) and the  
and  bands (500-600 nm) exhibited by Spy49_0662 following incubation with heme are 
indicative of heme-protein complex formation and are clearly distinguishable from the 
spectrum of free heme in solution (Free heme, Figure 6B). Heme binding by Spy49_0662 
was investigated further by titration of the apo protein with increasing amounts of free 
heme. A growing Soret band at 414 nm appeared in the resultant solution with 
incremental addition of heme (Figure 6D). The plot of the differential absorbance at 414 
nm as a function of heme these data established that spy49_0662 encodes a protein that 
specifically binds heme. We therefore named Spy49_0662 as HupZ (for heme utilization 
protein). The molar extinction coefficient for heme-bound HupZ was determined at 414 
nm using the pyridine hemochromogen method (145) and resulted in ε414 nm = 110,000 M-
1 cm-1.  
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3.3.2 Heme degradation by HupZ proceeds with the production of CO, ferrous 
iron, and a chromophore that absorbs at 660 nm 
Heme binding by HupZ, a likely cytoplasmic protein, supported the notion that it may be 
involved in heme trafficking or metabolism. We therefore asked if HupZ is capable of 
heme degradation. Oxidative cleavage of heme by HOs requires a source of reducing 
equivalents, which is provided in mammals by NADPH and CPR (146). While the native 
redox partner for most bacterial HOs is unknown, CPR is typically used to support heme 
catabolism by these enzymes in vitro. Heme degradation by holoHupZ was assessed first 
in a reaction containing human CPR and NADPH as reductants. The reaction was 
incubated at room temperature and the change in the UV-visible absorption spectrum was 
recorded at 10 min intervals for 1 hour (Figure 7A). Catalase was included in the 
reactions to prevent non-enzymatic degradation of heme by hydrogen peroxide. As 
shown in Figure 7A, the absorbance at 414, 530, and 560 nm decreased over time. The 
absorption peak at 340 nm, which is indicative of NADPH, also decreased rapidly during 
incubation (Figure 7A), suggesting that the pyrimidine nucleotide may be a limiting 
factor in the catalysis under our experimental conditions. We therefore included an 
NADPH regeneration system consisting of glucose 6-phosphate and glucose-6-phosphate 
dehydrogenase in the reaction (147). This addition allowed us to follow heme 
degradation without exhausting the NADPH (Figure 7B). Although the decrease in the 
Soret region was more rapid in the first 10 minutes, the Soret band continued to decrease 
for two-three hours. A growing peak at 660 nm followed the drop in the Soret peak and 
became more pronounced during the second hour of incubation (Figure 7C). Importantly, 
no significant spectral changes were observed during incubation of either free heme or a 
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control hemoprotein (holoShp) in the reaction buffer, indicating that heme in solution or 
in complex with protein does not react with NADPH under our experimental conditions 
(Figure 7D). The changes in the spectral properties of holoHupZ (during incubation with 
NADPH and CPR) imply that this enzyme progressively degrades the bound heme to 
form a product that absorbs at 660 nm. Our studies also show that human CPR can serve 
as an in vitro redox partner of HupZ. Some bacterial HOs can use alternative redox 
partners such as Fdx, FNR and/or ascorbate. We found however, that the inclusion of 
spinach Fdx and FNR or ascorbic acid instead of CPR in the HupZ reaction did not lead 
to spectral changes (Fig. 8 and data not shown).  
 
While canonical HOs release one of the meso carbons as CO during heme degradation, 
two bacterial enzymes were recently reported to catalyze heme breakdown by alternative 
mechanisms that involve the release of formaldehyde instead of CO (123) or the retention 
of the carbon atom after the ring cleavage (77). To test for CO formation by HupZ we 
used an established method that relies on the spectral signature of myoglobin-CO 
complex (107) and monitored the differential absorption spectrum of myoglobin during 
heme degradation. Myoglobin affinity for CO is 200 times higher than that for dioxygen 
(148), therefore if CO is released during heme breakdown in the presence of myoglobin it 
is likely to be captured. As can be seen in Figure 9, a shift in the absorption maximum 
from 410 to 420 nm was observed during the reaction. This spectral change was 
accompanied by the appearance of bands at 540 and 580 nm. The generated peaks at 420, 
540 and 580 nm are characteristic of myoglobin-CO complex (107). The plot of the 
absorbance at 410 and 420 nm as a function of time, demonstrates the conversion of the 
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starting myoglobin state (ferrous-dioxygen) to myoglobin-CO complex during the 
reaction course (Figure 9, insert). No changes in the spectrum of myoglobin were 
observed in control reactions without holoHupZ (Figure 9 insert, control reaction). 
Together, these experiments indicate that like the canonical enzymes, HupZ generates 
CO as one of the reaction products.    
 
To test whether HupZ releases iron from heme, we used the iron-indicator ferrozine. 
Ferrozine forms a stable magenta-colored solution with the ferrous iron, which exhibits a 
single sharp peak with maximum absorbance around 564 nm (149). Differential 
spectroscopy of HupZ catalysis of heme degradation in the presence of ferrozine 
demonstrated that the decrease in the Soret peak at 414 nm was accompanied by the 
concomitant increase of a peak at 564 nm, suggesting the formation of iron-ferrozine 
complex (Figure 10A). When free heme was incubated with ferrozine under the same 
conditions, no significant changes in absorbance were noticeable even after a long 
incubation period (Figure 10B). This observation indicates that ferrozine is able to 
capture iron only from solution but not from intact heme molecule. Using a standard 
curve, we determined that 20 M holoHupZ generated about 20 M iron over the course 
of the reaction, suggesting complete degradation of the bound heme (Fig. 10C).  
 
3.3.3 Crystal structure of HupZ 
HupZ was crystallized in the triclinic space group of P1 with two dimers in the unit cell. 
The crystallographic data and refinement statistics are summarized in Table 2. The 
structure was refined to the resolution of 2.0 Å with R and Rfree of 16.7 and 20.8, 
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respectively. The final structure has 119 residues per monomer with good electron 
density. Fourteen residues at the C-terminal end are disordered in the electron density 
maps and cannot be modeled unambiguously. The asymmetric unit consists of two HupZ 
homodimers (Figure 11A). All four monomers are essentially identical and can be 
superimposed with low pairwise RMSD values of 0.2-0.4 Å. The two dimers also 
superimpose with a very low RMSD of 0.2 Å, and the description here forth applies to 
both the dimers. The structure of the HupZ monomer contains six β strands, three  
helices and forms a typical split-barrel fold (Figure 11B). The six strands form an 
antiparallel -barrel. The first two helices lie across and block the two open ends of the β 
barrel. The third helix is packed against the side of the  barrel. HupZ dimerizes by 
stacking the β-barrel from two monomers at an angle of ~90.  
 
The new HupZ crystal structure was compared with known structures of other bacterial 
HOs. Comparison of HupZ with HugZ (128) [PDB ID: 3GAS], an HO from H. pylori, 
shows that the two dimers can be superposed by secondary structure matching to give an 
RMSD of 2.5 Å for 218 C atoms. HupZ is smaller and lacks the 80 residues N-terminal 
domain of HugZ, but the two proteins share the same split barrel fold for the C-terminal 
domain (Figure 11C). A heme moiety was observed in HugZ bound at the dimer 
interface, where it mainly interacts with the C-terminal residues. The flexible C-terminal 
region of HugZ plays an important role in heme binding and in particular His245 is 
involved in heme iron coordination and is conserved in related heme-utilization proteins 
(128). HupZ has a shorter C-terminal region that is truncated by 28 amino acids 
compared to HugZ. In addition, HupZ has no histidine in the superimposed structures 
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corresponding to His245 that coordinates heme iron in HugZ. In fact, the only histidine 
present in the HupZ sequence is located at the surface of the monomer and distal from the 
dimer interface. HugZ bears Arg166, which forms a water-mediated interaction with 
heme iron coordinating azide, and is essential for its activity (128). Substitution of 
Arg166 to Ala in HugZ results in loss of HO activity of HugZ. However, the amino acid 
structurally equivalent to Arg166 in HupZ is a glycine, which cannot form the equivalent 
interactions. The absence in HupZ of these crucial amino acid residues in HugZ 
emphasizes differences in the heme binding mechanism of the two enzymes. 
 
Comparison of HupZ with ChuZ (78) [PDB ID: 3SWJ] another HO from C. jejuni, shows 
that the monomers from the two structures can be superposed to an RMSD of 2.2 Å for 
108 C  atoms based on secondary structure matching. Similar to HugZ, ChuZ has a 
smaller 82 residue N-terminal domain, which is absent in HupZ, and a larger 169 residue 
C-domain with a split barrel fold resembling those in HugZ and HupZ (Figure 11D). The 
ChuZ crystal structure contains two bound heme molecules. The first heme binds at the 
dimer interface and is coordinated by His245 at the flexible C-terminal loop as seen in 
HugZ. The azide coordination of the other side of this heme and water mediated 
interaction with Arg166 are also conserved in ChuZ and HugZ indicating a common 
heme binding and reaction mechanism for these two enzymes. However, the ChuZ 
structure features a second surface heme bound to the N-terminal domain through 
residues His9 and His14. Alanine mutation of these two surface histidines together with 
Arg166 eliminates the heme degradation activity of ChuZ by blocking heme binding at 
the dimer interface and the non-enzymatic oxidation of the surface bound heme. His9 and 
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His14 of the N-terminal domain are conserved in both ChuZ and HugZ, which also 
indicate a conserved binding site. No equivalent histidines are present in HupZ, 
suggesting a different mechanism for heme binding.  
The third heme degrading protein with a split barrel fold, HutZ (79, 129) [PDB 
ID: 3TGV] from V. cholerae also can be superimposed with HupZ to an RMSD of 2.1 Å 
for 218 C atoms in the dimer by secondary structure matching. However, the HutZ 
crystal structure has no bound heme. Also, the first 12 residues at the N-terminal end and 
25 residues in the C-terminal end including the heme-Fe coordinating His were removed 
during cloning to prevent crystal twinning observed with the full length protein. Hence, 
this HutZ structure can yield little information on heme binding. 
  
3.4 Discussion 
Previous studies established that GAS uses dedicated surface receptors and membrane 
transporters to capture heme from host hemoproteins and relay it through the 
peptidoglycan layers and into the cytoplasm (30, 32, 132-135). GAS imports heme to 
satisfy nutritional requirements for metal iron (131, 134). Bacteria typically employ 
cytoplasmic HOs to release the iron from the porphyrin center. These enzymes catalyze 
the oxidative cleavage of one of the porphyrin meso carbon bridges at α, β, γ or δ 
positions and usually produce free iron, CO, and biliverdin (103, 104). To date, no HOs 
have been identified in GAS and the fate of the imported heme remained obscure. In this 
study, we describe a new GAS enzyme, HupZ, which binds and degrades heme in vitro. 
The recombinant HupZ can be isolated from E. coli in the apo form, which readily binds 
exogenous heme to saturation at a 1:1 ratio (Figure 6B and 6C) or in complex with heme 
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(after growth in medium containing 5-aminolevulinic acid and iron) (Figure 6D). The 
addition of NADPH to heme-bound HupZ (in the presence of CPR and NADPH 
regeneration system) triggered a progressive decrease of the protein absorption at the 
Soret region, 530, and 560 nm with an absorption peak at 660 nm (Figure 7). These 
spectral changes suggest the conversion of the heme bound to HupZ to a bilin that 
absorbs at 660 nm. Since catalase, which can scavenge hydrogen peroxide that may be 
produced in the reaction, was included in all reactions, catalytic conversion of the heme 
rather than coupled oxidation is responsible for the observed changes in the absorption 
spectrum. The absence of similar changes in reaction samples containing heme, free or 
bound to Shp, without HupZ shows that HupZ is required for this conversion.  
 
Spectroscopic assessment of myoglobin-CO complex formation during the HupZ reaction 
confirmed the release of CO from heme by HupZ (Figure 9) and suggests that HupZ 
heme degradation proceeded through the first two steps of a typical HO reaction. The last 
step in a standard HO reaction involves protonation and reduction of the iron in the 
ferric-biliverdin complex, which does not have significant spectroscopic features to 
produce free ferrous iron and biliverdin (which absorbs at the 640 to 680 nm range) (104, 
105, 150). The formation of the broad band at 660 nm by the HupZ reaction suggests 
therefore that this enzyme is able to carry on and liberate the iron. The demonstration of 
ferrous iron release is provided by titration with ferrozine. The magenta color and the 
band at 564 nm formed during the reaction indicate the formation of ferrozine-iron 
complex (Figure 10). Moreover, a direct correlation between heme consumption and the 
development of the ferrozine-iron complex was observed. Together, these observations 
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suggest that HupZ degrades heme in the presence of reducing equivalents (NADPH and 
CPR) and produces CO, ferrous iron, and an unidentified chromophore. Moreover, CO 
production implies that the catalytic mechanism of HupZ follows the canonical pathway 
and not those mediated by IsdG- or MhuD-type enzymes (77, 124).  
 
While HupZ quantitatively liberates iron from heme, this reaction is very slow and takes 
several hours to complete under our experimental conditions (Figure 9). Difficulties in 
releasing iron from the linear tetrapyrrole in vitro were reported for several HOs (73, 107, 
114, 124). The efficiency of this final step in heme catalysis often appears to depend on 
the nature of the redox partner. For example, in the presence of ascorbate, the human HO-
1 enzyme produces ferric-biliverdin complex and not free iron as it does with NADPH 
and CPR (150). The HO-1 like enzyme from C. diphtheriae (HmuO) catalyzes the 
formation of biliverdin and free iron with either NADPH/CPR or ascorbate. With 
ascorbate, however, the last step of the reaction is slow. Free biliverdin is observed only 
after two hours of incubation (107). Finally, many bacterial HOs cannot reduce and 
liberate the iron in vitro and thus catalyze the formation of ferric-biliverdin complex as 
the final product. These include HemO from N. meningitidis (109), BphO from P. 
aeruginosa (73), PigA from Pseudomonas species (114), and HutZ from V. cholerae 
(79). Considering the absence of sequence homology between HupZ and HO-1, it seems 
likely that the interactions between HupZ and the eukaryotic CPR are inefficient which 
may explain the sluggish iron release. Fdx/FNR or ascorbate could not support heme 
degradation by HupZ under our experimental conditions (Figure 8 and data not shown). 
Therefore, at this time, only NADPH/CPR was demonstrated to drive HupZ catalysis in 
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vitro. The identity of the cognate redox partner of HupZ remains elusive. The use of 
cognate redox partner in the HupZ reaction instead of CPR may allow for more efficient 
heme degradation in vitro, as was seen with the IsdI and IsdG enzymes while paired with 
IruO, their probable redox partner in vivo (151). 
 
HupZ does not share significant sequence homology with characterized HOs. To 
gain molecular insights into this new enzyme we solved the crystal structure of HupZ. 
The apo protein was crystallized as a homodimer with a split β-barrel conformation in 
each monomer, which contains six β strands and three α helices (Figure 11A). The 
structure of HupZ is similar to the common structural domain shared by the ChuZ, HugZ 
and HutZ proteins (Figure 11B-C) (78, 128, 129). Despite the overall structural 
resemblance, several important differences occur between HupZ and HOs from this 
family. HupZ is smaller and lacks the 80-residue N-terminal of HugZ and ChuZ, which is 
proposed to mediate coupled oxidation of heme (78). In addition, HupZ lacks the heme 
iron coordinating histidine residue (His245) that is conserved in both ChuZ and HugZ. 
The corresponding His170 in HutZ, however, was found to be unnecessary for heme 
binding (129). A phylogenetic tree was generated from the multiple sequence alignment 
of several HOs from various organisms (Figure 12). Members of the different families of 
HOs were grouped with their known respective relatives with high bootstraps values for 
the external nodes. This analysis located HupZ to a branch that is separated from the 
other HOs, indicating it belongs to a new subfamily of split β-barrel enzymes. The low 
bootstraps values for the internal nodes suggest that the bacterial HOs evolved 
independently and that this tree does not reliably represents the evolutionary direction of 
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this process. Putative ORFs that are homologous to HupZ are found in the genomes of 
GBS, Streptococcus dysgalactiae and other streptococci suggesting that HupZ is possibly 
a representative of a new family of enzymes in Streptococcus species.  
 In conclusion, we identified a new streptococcal enzyme that degrades heme in 
vitro generating CO, free ferrous iron, and unidentified chromophore. HupZ adopts a split 
β-barrel fold, thus it structurally resembles members of a recently characterized family of 
bacterial HOs. The structurally related HugZ produces δ-biliverdin, but final product of 
ChuZ and HutZ remained to be described (79, 80, 152). The significant differences 
observed between HupZ and these bacterial HOs indicate that HupZ may be a 
representative of a separate family of bacterial enzymes. The vast majority of HOs in 
bacteria are associated with iron uptake. Regulation by a metalloregulatory protein (such 
as Fur or DtxR) is one of their hallmarks (41, 116); other than BphO, the expression of 
bacterial HOs enzymes is enhanced during growth in low iron conditions. Likewise, 
MtsR, the global metal-dependent regulator in GAS represses the expression of hupZ 
gene [spy49_0662] (65). Regulation by iron availability supports the notion that HupZ 
degrades heme to provide GAS with iron. However, further analysis is necessary to 
unequivocally determine the role of HupZ in GAS physiology. 
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4 CHAPTER 3- HEME TOXICITY AND TOLERANCE IN GAS 
 
4.1 Introduction 
Heme is vital to many biological systems, ranging from planktonic marine 
microorganisms to the highly complex and evolved humans. The heterocyclic ring in 
heme, protoporphyrin IX (PPIX), co-ordinates metal iron (Fe+2); this architectural 
arrangement supports a wide array of roles upon presentation of an appropriate 
microenvironment. Hemoglobin and myoglobin, for example, use heme as a prosthetic 
moiety for the transport and storage of oxygen and other diatomic gases. A multitude of 
redox enzymes engages heme as a catalyst of electron transfer. Heme is also associated 
with energy conservation and biotransformation in processes such as photosynthesis and 
respiration. In addition, signal transduction pathways are integrated via heme due to its 
ability to bind gaseous ligands such as oxygen, carbon dioxide, carbon monoxide, and 
nitric oxide (81, 153, 154). Notably, heme in hemoproteins constitutes a major iron 
reserve used by invading microorganisms during infection (41, 155). Blood in particular 
is an immediate source of iron and heme for the majority of pathogens. Invading bacteria 
are often able to obtain heme directly from the circulating pool of hemoproteins. Some 
pathogens also deploy hemolysins to trigger erythrocyte destruction and hemoglobin 
release (41, 156, 157). 
 
Ironically, while heme is essential for many functions, the transitional nature of the 
coordinated iron renders it a significant pro-oxidant that can harm many cellular entities 
including DNA, proteins, cytoskeleton, and membranes (81, 158, 159). To prevent 
cellular damage and to control infections, mammals restrict the pool of free circulating 
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hemoproteins through scavenger proteins such as serum albumin, hemopexin (for heme), 
and heptoglobin (for hemoglobin) (160, 161). To minimize oxidative damage, the cellular 
levels of heme are managed by heme oxygenases. These enzymes degrade heme to 
biliverdin, which is then reduced to the cytoprotectant molecule bilirubin (162). Since 
heme could act as a menace, it is advantageous only in amounts that meet the bacterial 
requirements and, as long as it remains sequestered, preventing access to susceptible 
macromolecules (85). Bacteria that are exposed to heme and take advantage of it during 
infection had to develop strategies to manage its toxic effects. While we do not fully 
understand how bacteria avoid and manage the negative ramifications of heme exposure, 
recent studies have begun to shed light on some of the molecular mechanisms that are 
involved in this process (85, 95, 163). 
 
Heme tolerance in bacteria is typically based on tight regulation of heme uptake and 
degradation. Often bacteria employ Fur- or DtxR-like metallorepressors to orchestrate 
heme metabolism in response to iron availability (41, 164). In some cases, auxiliary 
defense systems that facilitate repair, detoxification, and expelling of heme surplus are 
activated when the cellular mechanisms for heme homeostasis are overwhelmed. A 
number of two-component systems (TCS) that coordinate the response to heme stress 
have been described in bacteria. The Heme Sensor System (HssRS) is a TCS that 
activates the expression of a heme efflux transporter (hrtAB) in Staphylococcus aureus, 
Bacillus anthracis, and possibly the Group B Streptococcus (GBS) (95, 165, 166). In 
response to heme pressure, the ChrAS TCS from Corynebacterium diphtheria inhibits the 
heme biosynthetic gene, hemA, and activates the transcription of the heme oxygenase 
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gene, hmuO, required for heme catabolism (167-170). Interestingly, in addition to 
putative HssRS TCS, GBS also codes for pefR, a heme-responding repressor (95). PefR 
binding to heme leads to derepression of two heme export systems, namely pefAB and 
pefCD (95). It is suggested that GBS uses PefR to fine-tune heme homeostasis, while it 
deploys the HssRS system in response to high heme exposure. 
 
As mentioned above, bacteria often detoxify, using active export systems that directly 
eliminate accumulated heme or its toxic byproducts. The efflux system, MtrCDE, in 
Neisseria gonorrhea, is crucial for bacterial resistance to hydrophobic agents and heme; 
overexpression of this machinery leads to increased bacterial burden in vaginal fluids 
(171, 172). GBS mutants in pefAB or pefCD genes are over-sensitive to heme and 
demonstrate increased accumulation of intracellular heme and PPIX (95). Respiration-
linked studies in Lactococcus lactis incriminated the hrtAB homologous genes ygfAB in 
heme efflux (173). A family of cytoplasmic proteins that bind and sequester heme forms 
another facet of heme tolerance. The proteins HemS of Yersinia enterocolitica, ShuS of 
Shigella dysenteriae, PhuS of Pseudomonas aeruginosa, and HmuS of Y. pestis are 
established members of this family (87, 120, 174-177). Interestingly, the enzymes SodC 
of Haemophilus ducreyi and AhpC of the GBS have both heme sequestration roles in 
addition to enzymatic activity (174, 178). Bacteria also degrade heme to alleviate 
toxicity. Heme oxygenases were described in several pathogenic bacteria (103, 179-181). 
Despite the clear role heme metabolism has in pathogenesis, our understanding of heme 
tolerance is lacking in numerous pathogens. 
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 The Group A Streptococcus (GAS) is a Gram-positive obligate human pathogen. GAS 
infections range from mild diseases such as pharyngitis and impetigo to invasive and 
systemic manifestations, including necrotizing fasciitis and streptococcal toxic shock 
syndrome. GAS can also produce post-infection complications such as 
glomerulonephritis and rheumatic fever (182). In the absence of a vaccine, GAS 
infections are commonly treated with β-lactam antibiotics.  However, due to the swift 
progression rate and extent of tissue damage, surgical intervention is often required to 
manage invasive GAS infections (183). The grave nature of invasive GAS infection is 
attributed to many virulence factors, including its β-hemolytic property that causes 
massive erythrocyte and tissue lysis (184). GAS requires iron for growth and the 
pathogen can fulfill its needs for the metal by acquiring heme from lysing erythrocytes 
(30, 131). Heme acquisition is mediated by the sia (streptococcal iron acquisition) 
operon that facilitates heme relay and transport across the bacterial membrane (32, 132, 
133, 185, 186). In vivo studies on a second operon named siu (streptococcal iron uptake) 
linked it to the uptake of heme and ferric ion (30). Although heme receptors and transport 
proteins have been identified, our understanding of heme metabolism in GAS is still 
incomplete. The focus of this study was to fill in the knowledge gaps in GAS heme 
tolerance. Here, we show that excess heme is inhibitory for the growth of GAS in vitro; 
heme exposure caused a global transcriptome shift wherein it significantly up regulated 
genes that are important for redox stress, which includes sensing and management along 
with protein damage and rescue.  
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4.2 Materials and Methods 
 
4.2.1 Bacterial strains and growth conditions.  
Strains and plasmids used in this study are listed in Table 3. GAS was grown under static 
conditions at 37 °C in Todd-Hewitt broth with 0.2% (wt/vol) yeast extract (THY broth, 
Difco Laboratories) or in C-medium consisting of 0.5% Proteose Peptone #3 (BD), 1.5% 
yeast extract (BD), 10 mM K2HPO4, 0.4 mM MgSO4, 17 mM NaCl, adjusted to pH 7.5 
(187). In some experiments, hemin chloride (Sigma) from stock solutions prepared in 
DMSO was added to the growth media at different concentrations. E. coli cells were used 
for cloning and protein expression purposes. E. coli was grown aerobically in a Luria-
Bertani medium (pH 7.0) supplemented with kanamycin (30 μg/ml) at 37 °C.  
 
4.2.2 Determination of the minimal inhibitory concentration (MIC). Agar 
dilution method  
This procedure was performed as described in (188) with minor modifications. Briefly, 
the turbidity of overnight grown cultures in C-media was adjusted to OD600nm = 0.08-0.1, 
representing the turbidity of 0.5 MacFarland’s acidified barium chloride standard as 
described (Washington, 1974) and spotted (1 μL) onto C-medium agar containing 
varying concentrations of heme. The plates were incubated overnight at 37 °C and the 
minimal heme concentration that did not allow for significant bacterial growth was 
determined. Broth macrodilution method: this method was performed as per the 
instruction of (188). In brief, THYB containing heme at a range of 0-100 μM in 5 μM 
intervals was inoculated with GAS cells (OD600nm = 0.05) and incubated at 37 °C for 17 
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hours. The minimal heme concentration that did not support growth (OD600nm ≤ 0.2) was 
determined. Disc diffusion method: this procedure was adapted from (189). Briefly, 
sterile Whatman filter paper discs (8.0 mm diameter and 1.2 mm width) were submerged 
in 10 mM heme (in DMSO) and impregnated onto C-media agar that was plated with 0.1 
ml of GAS culture (final OD600 nm = 0.1). The plates were incubated at 37 °C for 17 hours 
and the zone of clearance around the discs were measured.  
 
4.2.3 Thiobarbituric acid-reactive-substances (TBARS) assay for lipid damage. 
 GAS culture samples with equal cell numbers were harvested 30, 60, and 90 min 
following treatment with 4 μM heme (in 0.035% DMSO) or with mock (0.035% DMSO, 
control) and washed twice with phosphate buffer saline, pH 7.4 (PBS). The resulting cell 
pellets were resuspended in 5 ml of PBS with lysozyme (1 mg/ml, Sigma) and 400 U of 
mutanolysin (sigma) and incubated at 37 °C for 30 min. The cells were then subjected to 
sonication (5 sec., 10% amplitude). TBARS formation in the membrane samples was 
quantified using the TBARS assay kit (ZeptoMetrix Corporation) according to the 
manufacture’s recommendations. Briefly, 100 μl cell lysate samples were treated with 
100 μl of SDS and 2.5 ml of the TBA reagent and incubated at 95 °C for 60 min. The 
sample supernatant was collected following 10 min incubation on ice by centrifugation 
(15 min at 835×g). The absorbance at 532 nm (indicative of TBARS) was measured 
using the DU 730 Life Science UV/Vis spectrophotometer. The amount of TBARS in the 
experimental samples was derived from a standard curve generated using the 
malondialdehyde (MDA) reagent supplied with the kit. 
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4.2.4 Detection of protein damage.  
The TBARS assay was followed as above except the cell pellets were washed twice with 
TSM buffer (100 mM Tris, 500 mM sucrose, 10 mM MgCl2, pH 7.0), resuspended in 0.5 
ml of TSM with 400 U of Mutanolysin (Sigma) and incubated at 37 °C for 30 min. The 
protoplasts were centrifuged at 20,000×g for 5 min at 4 °C, suspended in 0.2 ml of lysis 
buffer (50 mM Tris-HCl, 60 mM KCl, 10 mM MgCl2, pH 7.0, 2% β-mercaptoethanol) 
and subjected to sonication (10 Sec. 10% amplitude). The membrane components were 
collected by centrifuged at 100,000×g for 30 min at 4 °C. The supernatant was retained as 
a cytoplasmic fraction and pellets were resuspended in 0.2 ml of lysis buffer and were 
considered as the membrane fractions. Protein damage was detected using the OxyBlot™ 
protein oxidation detection kit (Millipore) according to the manufacturer’s instructions. 
In this assay, oxidized proteins are derivatized with 2,4-dinitrophenylhydrazine (DNP), 
which is then detected with primary antibodies specific for DNP and secondary antibody 
conjugated to horseradish peroxidase (HRP) using a chemiluminescence protocol. The 
intensity of the signal in individual lanes was quantified using ImageQuant LAS 4000 
and the ImageQuant TL software (GE). 
 
4.2.5 RNA extraction.  
Cell samples were harvested 30, 60, and 90 min following heme or mock treatment by 
centrifugation (5000×g for 20 min) at 4 °C. RNA was extracted from the cell pellet using 
the RiboPure™ RNA purification kit (Ambion) followed by DNaseI digestion (Ambion) 
performed according to manufacturer's instructions. Microarray analysis was performed 
with total RNA extracted from 90 min post treatment cell samples. Real-time RT-PCR 
  
 
46 
transcript analysis for selected genes was performed using total RNA extracted from all 
three-time points post treatments. 
 
4.2.6 Microarray analysis and Real-Time RT-PCR validation.  
The GAS microarray used in this study (190)  consists of 2,328 70-mer oligonucleotide 
probes targeting unique non-repetitive ORFs from the sequenced genomes of serotypes 
M1 (SF370), M3 (MGAS315), and M18 (MGAS8232). Probes were synthesized by 
Qiagen Operon with a melting temperature of 76 ± 5 °C, ≤ 70% cross-hybridization 
identity to another gene within the same strain, ≤ 20 contiguous bases in common with 
another gene, and probe location within 3′ end of ORF. Microarrays were printed at 
Microarrays Inc. (http://www.microarrays.com), with 10 pl of each oligonucleotide probe 
spotted onto slides (UltraGAPS2; Corning) using a 12-pin contact printer. The microarray 
hybridization was performed as previously described (191). Briefly, 10 μg of DNase I-
treated total RNAs to be compared were used for reverse transcription into single-
stranded cDNA using 200 U Superscript II reverse transcriptase (Life Technologies), 6 
μg random hexamers, 1X first strand buffer, 10 mM dithiothreitol (DTT), 0.5 mM dATP, 
0.5 mM dCTP, 0.5 mM dGTP, 0.3 mM dTTP and 0.2 mM of amino-allyl dUTP. The 
mixture was incubated at 42 °C for 2 h and the reaction stopped by addition of 10 μl 
0.5 M EDTA and 1 M NaOH. Amine-modified cDNA was purified by ethanol 
precipitation followed by chemical labeling with Cy3- or Cy5-NHS-ester fluorescent 
dyes (GE Healthcare) in a final step. Yield and incorporation of dye was determined 
using a Nanodrop ND-1000 (Thermo Scientific). Slides were pre-hybridized in a 50 ml 
solution of 5X SSC, 0.1% SDS and 1% BSA for 30 min at 42 °C, washed 4X in water 
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and once in isopropanol, then dried by brief centrifugation. Labeled probes were 
resuspended in hybridization buffer (30% formamide, 5X SSC, 0.1% SDS, 0.6 μg/μL 
salmon sperm DNA) and hybridized to the microarray slides in a 42 °C water bath for 16-
20 h. Slides were washed twice in a low stringency buffer (2X SSC, 0.1% SDS) at 55 °C 
for 5 min, twice in a medium stringency buffer (0.1X SSC, 0.1% SDS) at room 
temperature for 5 min and finally twice in a high stringency buffer (0.1X SSC) at room 
temperature for 5 min, and then dried by brief centrifugation. Synthesized cDNA from 
each RNA sample from three independent cell cultures was hybridized on three separate 
microarray slides (biological replicates), and independently synthesized cDNA from each 
of these same RNA samples was hybridized in a repeat dye-swap experiment (technical 
replicates) to test technical reproducibility. Slides were scanned using an Axon 4100A 
personal array scanner and GenePixPro 6.0 software (Molecular Devices). Data obtained 
from MGAS5005 cells incubated in the presence of DMSO or 4 µM of heme were 
compared for twofold changes in expression, ≥ 2.0 or ≤ 0.50 with Acuity 4.0 software 
(Molecular Devices). Using a ratio-based normalization, data were normalized by the 
ratio of the means (635/532) and samples were removed when four out of the six 
experiments did not show significance. Data was validated on 11 independent genes by 
real-time RT-PCR as described below.  Correlation coefficients for the arrays were 
determined by plotting the log value of the array on the x-axis to the log value of the real-
time RT-PCR on the y-axis. An equation determining the line of best fit was determined, 
and the resulting R2 value was calculated to be 0.889.  Array data was submitted to the 
Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information 
under the accession number GSE61415. 
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4.2.7 Quantification of expression by real-time RT-PCR.  
For microarray data validation, real-time RT-PCR analysis was carried out using primers 
in Table 4 as follows: 25 ng of DNaseI-treated total RNAs were added to SYBR green 
master mix (AB) containing 5 µg of each specific real-time primer for the one-step 
protocol. The real-time RT-PCR experiments were completed using a LightCycler 480 
instrument (Roche), and levels represent the ratio of non-treated to treated experimental 
values relative to the level of expression of gyrA transcript as an endogenous control. For 
expression of the pefRC operon, a SYBR Green based quantitative PCR reactions were 
performed using the Power SYBR® Green RNA-to-Ct™ 1-Step Kit (AB) on 7500 Fast 
Real-Time PCR machine (AB) according to the manufacturer’s specifications. Briefly, 
the reaction mixture (20 µl) contained, 10 µl of RT-PCR Mix (final 1X), 10 nM of each 
forward and reverse primers, 25 ng of total RNA, and RT enzyme Mix in 1X final 
concentrations. The relative quantification with comparative ΔΔCT method was 
employed to calculate differences in pefRC expression levels at different times after heme 
exposure. The relative expression levels of pefR and pefC genes were normalized to the 
level of rpsL transcript as an endogenous control. The levels of transcripts in heme 
treated samples were compared to the control samples. 
 
 
4.2.8 In silico analysis.  
The PefR binding motif was identified within the putative promoter region of 
MGAS5005 spy_0195 (pefR) using Multiple Em for Motif Elicitation (MEME) suit 
hosted by the National Biomedical Computation Resource (192). The outcome was 
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further analyzed by the MAST application of MEME for its genome wide occurrence 
within the upstream sequences of GAS under both the stringent (E value ≤ 0.01) and 
relaxed (E value ≤ 10) parameters. All of the sequences were acquired from Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database (193) for comparative sequence 
analysis; sequences were aligned using ClustalW (194).  
 
4.2.9 Cloning, overexpression, and purification of PefR.  
The spy_0195 ORF was amplified from GAS MGAS5005 genomic DNA by PCR using 
primers ZE515 and ZE516 (Table 4). To generate pAJS11 plasmid (Table 3), the PCR 
fragment with pefR ORF was cloned into the pRham™ expression vector (Lucigen) by 
Expressioneering™ technology and introduced into E. cloni® 10G competent cells. The 
cloning was confirmed by sequence analysis. For PefR expression, cells harboring 
pAJS11 were induced at OD600nm = 0.8 with 0.2% rhamnose. The cells were harvested 
(8,000×g for 5 min at 4 °C) following 16 hours incubation at 28°C. The resulting pellets 
were resuspended in extraction buffer (20 mM Tris pH 8, 100 mM NaCl, 0.1% Triton X-
100) containing 0.5 mg/mL Complete, mini-EDTA-free protease inhibitor cocktail 
(Roche), sonicated and the cell debris were removed by centrifugation. The resulting 
lysate was purified over 5 ml HisTrap™ HP (GE) nickel affinity column. Protein 
fractions were dialyzed overnight in sodium phosphate buffer (SPB: 20 mM sodium 
phosphate, 500 mM NaCl pH 7.4). Expression of the recombinant PefR was evaluated by 
SDS-PAGE and western blot analysis with mouse anti-His antibodies (Sigma).  
 
4.2.10 Heme and PPIX binding assay.  
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Heme binding by PefR was assessed spectroscopically as described in (125, 185) with 
minor modifications. Briefly, an increasing concentration of hemin chloride (2-30 μM) 
was added to both the test cuvette containing 10 μM of PefR protein in SPB and the 
reference cuvette (containing SPB alone) and the changes in absorbance across the 
wavelength of 250 – 700 nm region were recorded every 6 min. The PefR to heme 
stoichiometry and dissociation constant (Kd) were determined by plotting the absorbance 
at 435 nm as a function of the heme concentrations. The extinction coefficient (εmax) for 
PefR was calculated from the hemocromogen method described in (195). All of the 
spectroscopic measurements were made using the DU730 Life Science UV/Vis 
spectrophotometer (Beckman Coulter). PPIX binding was tested by titrating PefR (5 μM) 
with 0-6 μM PPIX (in 0.5 μM increments) prepared in acidified 
methanol:dimethylformamide (1:1). The changes in absorbance were recorded. 
 
4.3 Results 
 
4.3.1 Excess of heme is inhibitory to the growth of GAS.  
Host heme is the immediate source of iron during infection for invading pathogens such 
as GAS. Recent studies demonstrated that bacteria must maintain the intracellular levels 
of heme at equilibrium in order to benefit from its nutritional value, while eluding the 
toxicity that is associated with heme overload (95, 166, 196). In this work, we began 
evaluating the impact of heme on GAS physiology. We found that the addition of a disc 
saturated with 10 mM heme onto agar plates seeded with a confluent lawn of GAS 
resulted in a zone of clearance similar to those observed with antibiotic-impregnate discs. 
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This observation indicates that heme can have a bacteriostatic effect on GAS (Table 5). 
To compare the sensitivity to heme among GAS isolates we determined the MIC values 
of heme using two common methods (Table 5). The agar dilution assay employs solid C-
medium containing varying concentrations of heme. We determined that the heme MIC 
in this method is between 10 to 20 μM with the nephritogenic M49 GAS skin isolate, 
NZ131 (197, 198), exhibiting the highest sensitivity of all GAS strains tested. The highly 
pathogenic M1T1 MGAS5005 strain (199) as well as clinical isolates from patients with 
invasive diseases (Table 3) demonstrated higher heme tolerance. In the broth dilution 
assay, we measured bacterial growth in THYB supplemented with varying heme 
concentrations. This method resulted in higher values of heme MIC (30-50 μM) for 
MGAS5005 and the clinical isolates. However, both methods indicated that the invasive 
strains were more resistant to heme than NZ131. 
 
4.3.2 Exposure to sub-lethal heme levels cause lipid peroxidation in GAS.  
To learn why heme is detrimental for GAS growth, we investigated its impact on GAS 
macromolecules. Heme is reported to damage directly or through the generation of 
reactive oxidative species the integrity of membrane lipids (81, 200). Therefore, we 
evaluated the extent of lipid peroxidation in GAS following heme exposure. Using low 
heme concentration that could still support cell growth when applied at the early 
logarithmic phase allowed us to examine the kinetics of damage production and later the 
bacterial transcriptome response to heme. As seen in Figure 13A, the addition of 4 μM 
heme to MGAS5005 at the early logarithmic phase of growth did not result in a 
significant change in the bacterial growth profile. To detect lipid peroxidation, we used 
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an established method that relies on the tendency of oxidized lipids to react with a 
thiobarbituric acid (TBA) reagent to form adducts (named TBARS) that absorb at 532 nm 
(201). The time course of TBARS production in GAS cells exposed to heme (or in 
control samples) was quantified using a standard curve (Figure 13B). Significantly higher 
occurrence of lipid peroxidation was observed in all of the heme-treated samples 
compared with control samples (Figure 13C). Lipid peroxidation was the highest (22.5 
fold over background) 30 min after heme treatment; while lower levels (~5 fold over 
background) were found in the samples collected 60 and 90 min post-heme treatment 
(Figure 13C), indicating possible repair mechanism. In eukaryotes, membrane repair 
involves enzymes such as phospholipase A2 that hydrolyse peroxidized fatty acid esters 
and glutathione peroxidase (202, 203).   
 
4.3.3 Exposure to heme damaged membrane proteins.  
We next evaluated the effect of heme on GAS proteins. Oxidation introduces carbonyl 
groups into protein side chains that can then react with 2,4-dinitrophenylhydrazine 
(DNPH) to generate 2,4-dinitrophenylhydrazone (DNP) derivatives (204). To monitor 
protein oxidation in GAS, membrane and cytoplasmic proteins were extracted from 
culture samples collected at 30, 60, and 90 min post treatment and allowed to react with 
DNPH. Oxidation was then visualized by immunoblot with antibodies specific for DNP 
and the damage was quantified by densitometry. Analysis of the membrane fractions 
revealed that the anti-DNP antibody strongly reacted with all of the samples from heme 
exposed cells (Figure 14A, upper panel). While general staining confirmed the presence 
of proteins in all samples (Figure 14A, bottom panel), protein oxidation was only 
  
 
53 
observed in the heme-treated cells in the early sample. At the later time points (60 and 90 
min) some background oxidation also occurred in the control samples. In all cases 
though, a significantly higher amount of protein damage was observed in the heme-
exposed cells compared to the controls (Figure 14C). In addition, the degree of protein 
oxidation was the highest in the 90 min samples. Similar analysis of cytoplasmic proteins 
did not reveal detectable damage (Figure 14B); therefore, protein oxidation following 
heme exposure is primarily linked to the membrane fraction under our experimental 
conditions. 
 
4.3.4 GAS demonstrates adaptation response to heme.  
When overnight cultures of NZ131 grown in heme-free medium were inoculated into 
medium containing 1 M heme, which is below the growth inhibiting concentrations at 
the early logarithmic phase, an extended lag phase that lasted for more than 8 hours was 
observed (Figure 15). Although exposure to heme inhibited growth initially, the cultures 
reached after overnight incubation the cell density observed in cultures that grew in 
heme-free medium (data not shown). To test for possible adaptation to environmental 
heme, GAS cells were grown overnight in the presence of 0.1 M heme before they were 
inoculated into medium with 1 M heme. Indeed, pre-exposure to low heme level 
eliminated the extended lag period (Figure 15). These observations suggest that the 
treatment with low level of heme-triggered adaptation to environmental heme. 
 
In light of recent evidence that bacteria can sense and respond to heme (95, 163, 196, 
205) and with evidence for a similar response in GAS, we wanted to gain insight into the 
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pathogen’s mechanisms for heme sensing and tolerance. We examined the differential 
global gene expression pattern between GAS cells subjected to heme stress (4 μM) and 
control treatment. Total RNA was isolated from cells 90 min post treatment and analyzed 
using a 70-mer oligonucleotide microarray (representing GAS genomes M1, M3 and 
M18) (190). Our data showed a significant shift in the transcript profile of different genes 
and operons in response to heme stimulus; referred to as the ‘GAS heme stimulon’. This 
stimulon involved changes in 163 total genes, including 79 genes that were up regulated 
and 84 genes that were down regulated (Figure 16 and Supplementary Table 1). The 
array analysis was validated by quantitative RT-PCR (qPCR) on 11 differentially 
regulated genes (Supplementary Table 1), showing a strong correlation, with an R2 value 
of 0.889 (Supplementary Figure 1). 
 
Genes that were down regulated significantly in response to heme are found in the 
categories of metabolic pathways, sugar and metabolite transport, and two-component 
system (TCS, Figure 16A). Of particular interest is the down regulation of the TCS, 
trxSR. The response regulator, TrxR activates the Mga virulence regulon in GAS, and a 
trxR mutant is attenuated for virulence in a murine infection model (206, 207). Therefore, 
environmental heme may impact the expression of key virulence factors in GAS via the 
TrxSR/Mga pathway. Since the TrxSR system is implicated in asparagine sensing, our 
observations also imply that the damage to the cell envelope introduced by heme is 
associated with increased levels of asparagine (or other amino acids) (206, 207). In 
contrast, heme-activated genes and highly expressed transcripts encode for protein 
folding and degradation (such as groEL/ES ~8 fold, DnaJ/K 3-4 fold, and clpE/L ~4 fold) 
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and components of the Clp protease machinery (clpCP- 2.5 fold) (208, 209) (Figure 
16B). In addition, the GAS heme-activated stimulon includes genes whose functions are 
linked to regulation of redox stress management, including spx (5 fold) and ctsR (2.5 
fold) (210, 211). Accordingly, members of the downstream genes of these regulators 
were also activated by heme such as thioredoxin (trx ~2.5 fold) and oxidoreductases (3 
fold). Finally, the expression of two TCSs was also up regulated in response to heme 
exposure, including the pneumococcal-like TCS homologous system, ciaHR (~2.3 fold) 
(212) and the ihk/irr TCS (2.5 fold) involved in GAS response to oxidative stress and 
survival within phagocytes (213).  
 
4.3.5 Identification of the pefRCD locus in GAS.  
The transcriptomic analysis also revealed that several putative efflux proteins also 
showed an increase in transcriptional activity in response to heme stress. These included 
a 3-gene cluster (MGAS5005 spy_0195, 0196, and 0197) with homology to the pefRCD 
genes from GBS (95). Since the pefRCD genes are important for the management of 
heme stress in GBS, we focused our attention on their heme-induced homologs in GAS. 
Comparative sequence analysis demonstrated that the putative GAS genes, spy_0195 
(84% similarity; 56% identity), spy_0196 (76% similarity; 48% identity), and spy_0197 
(76% similarity; 51.3% identity) show significant sequence homology to the GBS 
pefRCD genes, respectively (Figure 17). In addition to the high sequence homology 
demonstrated by each of these GAS genes, the genomic arrangement of the GBS pefRCD 
locus and its immediate chromosomal location are also conserved in all of the published 
GAS genomes (Figure 18A). Moreover, using the MEME algorithm, we identified a 17-
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bp inverted repeat region within the putative promoter of spy_0195 that shared 76% 
identity with the PefR binding site from GBS (Figure 18A). Based on this sequence 
conservation and the observed induction by heme, we hypothesized that like GBS, the 
above-mentioned GAS genes encode a heme dependent repressor (spy_0195) and an 
ABC heme exporter (spy_0196 and spy_0197) and named them pefRCD, respectively. 
 
We examined the time course of pefRC expression in response to heme by qPCR (Figure 
18B). As seen in the microarray analysis, the expression of pefR and C was comparable 
to one another in all of the time points, supporting an operon structure. Heme exposure 
resulted in an increase of pefR and pefC expression over time, reaching 2.5 fold over 
background at 30 min, 4.5 fold at 60 min and remained high at 90 min post treatment. 
This temporal increase in pef expression in response to heme insinuates an active 
participation of these genes in heme tolerance.  
 
4.3.6 GAS PefR binds heme and PPIX with high affinity.  
In GBS, PefR is a MarR-like repressor that binds to DNA and blocks the transcription of 
both pefRCD and pefAB operons. In this system, heme acts as an inducer that binds to 
PefR protein to alleviate repression. The GAS protein shares 43% identity and 74% 
similarity with PefR from GBS (Figure 17), implying the two proteins may function in a 
similar manner. We cloned the pefR gene from GAS and expressed it as an N-terminal 
hexahistidine (6x-His) fusion protein. SDS-PAGE and western blot analysis of the 
recombinant protein following purification from E. coli confirmed the presence of a 
single protein at the expected size that reacts with anti-his tag antibodies (Figure 19A and 
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data not shown). Interestingly, the purified PefR had a light brown color (Figure 19B, left 
inset) and exhibited an absorption in the Soret region (435 nm). Upon titration with free 
heme, PefR displayed a growing Soret band and concomitant increase in absorption at 
530 and 560 nm (β and α bands of heme). These spectral features are characteristics of 
heme bound protein and are easily separated from the absorption displayed by heme that 
is free in solution (214). The holo-PefR maintained a bright red color after the removal of 
heme excess by gel filtration and dialysis (Figure 19B, right inset). Therefore, PefR was 
purified from E. coli with some heme and readily bound heme in vitro. The plot of 
changes in absorbance at 435 nm as a function of heme concentrations indicated a 
binding stoichiometry of 1:2 (PefR:heme, Figure 19C). We determined the dissociation 
constant (Kd) for PefR by fitting the plot of changes at 435 nm in the modified Hill’s 
equation (215). We found the Kd to be 10 μM and Hill’s coefficient (nH) to be 1.3, 
greater than 1 (216). The molar extinction co-efficient at 435 nm of holo-PefR was 
determined using the pyridine hemocromogen method (195) and resulted in ε435 = 30,407 
M-1cm-1. Similarly, titration of PefR with PPIX indicated that it could also bind PPIX in 
1:1 stoichiometry with Kd of 9 μM (Figure 20).  
 
4.4 Discussion 
 
It is the biochemical properties of heme that contribute to its characteristics as a double-
edged sword in a variety of biological systems. Heme toxicity in humans stems from the 
lysis of erythrocytes due to disease, inflammation, or physical damage, which could raise 
the heme levels in the bloodstream up to 20 μM (217, 218). The generation of reactive 
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oxygen species, alteration in membrane permeability, damage to macromolecules, and 
decrease in the pool of reductants are some of the cellular mayhem that follows heme 
overload in eukaryotes (218). In bacteria, despite the importance of heme to physiology 
and pathogenesis, the molecular mechanisms for heme toxicity and tolerance are poorly 
understood (85). In this study, we probed these processes in GAS for the first time and 
established that heme stress is very significant to the physiology of the -hemolytic 
pathogen; heme in excess inhibits GAS growth and exposure to low heme levels damages 
membrane lipids and proteins. We demonstrated the presence of an adaptation process to 
environmental heme in GAS and revealed a comprehensive transcriptome response to 
excess heme exposure. Finally, our findings also implicate a new gene cluster, pefRCD, 
in GAS heme sensing and tolerance.  
 
We found that heme tolerance in GAS depends on medium type, growth conditions and 
genetic background (Table 5). Differences in bacterial metabolism, aeration, and cell-to-
cell contact may all affect the bacterial sensitivity to heme. In addition, the THY medium 
is prepared from brain and heart infusion and is likely to contain some heme. Growth in 
THYB therefore, may allow for bacterial adaptation, possibly contributing to the higher 
heme MIC values observed in this medium. A significant variation in heme tolerance was 
exhibited by different strains of GAS; with NZ131, a serotype M49 skin isolate (197, 
198), demonstrating the lowest heme tolerance, whereas the more invasive strains such as 
M1T1 MGAS5005 (199) and other clinical isolates showing higher heme resistance. It is 
tempting to speculate that these variations in heme sensitivity might add to the inclination 
of different GAS strains to colonize certain sites and to their invasive potential.  
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The absence of significant damage to cytosolic proteins in GAS suggests that the 
membrane is the primary target of heme in this bacterium (Figures 13 and 14). This 
observation is in accordance with findings made in S. aureus (219) and is likely to result 
from heme accumulation in the cell envelope. The negative regulation of the heme uptake 
machinery works to limit the amount of heme that can reach the GAS cytoplasm (30, 32, 
220). In addition to active import, heme can diffuse through biological membranes, albeit 
with slow diffusion rates that can lead to accumulation in this compartment. Indeed it is 
well established that heme surplus tends to accumulate in the membranes of the 
eukaryotic cells, where it can be transformed into highly reactive species (81, 161). There 
is less information regarding heme localization in bacteria; however, studies in S. aureus 
suggest a similar buildup in the cell envelope (221). In addition to the preferential 
localization of heme outside of the cytoplasm, the reducing environment and the detox 
mechanism induced by heme (e.g. heat shock and redox factors) could mitigate some of 
the oxidative effects of the heme in this compartment. In this study we only probed the 
impact of heme at 4 M, a concentration that is below the MIC level in early exponential 
phase, and for 90 min post treatment. Further investigations are needed to determine if 
heme at higher concentrations or after longer exposure time is affecting other cellular 
compartments.  
 
The extended lag period that is observed when naïve GAS cells are introduced into 
medium containing heme and the absence of the growth delay in cells that were pre-
exposed to low heme levels (Figure 15) provide strong evidence for the presence of heme 
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sensing and coping mechanisms in GAS. Indeed, microarray analysis indicated that heme 
triggers comprehensive changes in GAS transcript levels (Supplementary Table 1 and 
Figure 16A). The shift in the expression of regulatory proteins such as spx, ihk/irr, ctsR, 
and hrcA and their downstream-regulated genes, suggests that heme leads to significant 
redox, oxidative, and protein damage (Figure 16B). Spx is an RNA polymerase binding 
protein with CXXC redox-sensing center that acts to restore thiol balance by controlling 
redox enzymes and antioxidants formation (222). The ihk/irr TCS regulates oxidative 
stress genes that protect GAS from killing by phagocytic cells and hydrogen peroxide 
(213, 223). The induction of this regulatory system is consistent with ROS formation and 
cell envelope damage following heme exposure. The master regulators CtsR and HrcA, 
originally classified as class III and class I heat shock gene regulators, respectively, have 
been associated with a wide variety of stresses such as temperature shifts, antibiotics, 
carbonyl, electrophiles, etc. (224, 225). Here we show their association with heme stress 
and the elevated expression of chaperones and clp proteases further corroborates our 
hypothesis of heme-induced protein unfolding and findings of protein oxidation.  
 
Heme treatment also resulted in significant inhibition of the genes encoding lactate 
oxidase (lctO) and of a V-type ATP synthases system (ntpKCFABD). LctO reaction leads 
to hydrogen peroxide production that can exacerbate the damage induced by heme (226, 
227). The down regulation of the proton pump may serve to increase the reducing power 
at the cell surface. Further selective down regulation of genes such as citDEFX and up-
regulation of fruRBA, which are involved in import and utilization of citrate and fructose, 
respectively, could indicate a metabolic state that is more conducive to detoxification.  
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Le Breton et al. recently used a mariner-based transposon library to screen for genes that 
are important for GAS survival in human blood (228). Comparing the heme stimulon 
identified in this study to the findings of Le Breton et al. revealed significant overlap, 
including clpE and L, fhs.2, fruA, citF, trxS, lacZ, and the has operon. This comparison 
suggests that heme, directly or indirectly, act as a signal that mediates adaptation in vivo 
and that the management of heme toxicity is relevant to GAS pathogenesis, in particular 
during spread through the blood.  
 
The heme stimulon in GAS also includes three genes (spy_0195-7) that share high 
homology to the GBS pefRCD genes. In GBS these genes code for a heme responsive 
repressor (PefR) from the MarR-like family (229) and to an ABC heme exporter (PefCD) 
(95). While the presence and genomic arrangements of pefRCD are highly conserved 
among different GAS strains (Figure 17 and 18), we failed to identify homologues to 
pefAB (and hrtAB) that also participate in heme tolerance in GBS and other Gram-
positive bacteria. The high degree of sequence similarity and the temporal increase in 
expression in response to heme stress (Figure 18B) suggest that the 3-gene locus encodes 
for a true homologue of the pef operon. This hypothesis is further supported by the 
identification of a putative PefR heme-binding box that is highly comparable to that of 
PefR from GBS (Figure 18A) (95) and by our heme and PPIX reconstitution experiments 
(Figures 19 and 20). The ability of PefR to coordinate two heme molecules and curve 
fitting data demonstrating positive Hill’s coefficient of cooperativity most likely suggest 
that the binding of heme at one binding site increases the affinity of heme binding at 
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another site (215, 216). Further experiments are underway to determine if and how heme 
and PPIX are modulating PefR binding to DNA and to establish the role of this 3-gene 
cluster in heme and protoporphyrin tolerance in GAS. 
 
To the best of our knowledge our work is 1) the first effort to characterize GAS 
mechanisms for heme toxicity and tolerance; 2) shows that environmental heme 
constitutes a significant redox stress in GAS with damaging effects on membrane lipids 
and proteins; 3) provides evidence for heme sensing and adaptation that involves global 
transcriptome shifts; and 4) links heme stress to several key regulators and TCS systems 
of this important human pathogen. 
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5 CHAPTER 4 - THE PEFCD IS A MDR SYSTEM THAT EXPORTS HEME 
AND CONFERS RESISTANCE TO HEME AND DOXORUBICIN IN GAS  
 
5.1 Introduction 
Streptococcus pyogenes or Group A Streptococcus (GAS) is a Gram positive, β- 
hemolytic, human pathogen transmitted via respiratory droplets and direct contact. GAS 
is responsible for a diverse spectrum of diseases ranging from superficial (e.g., 
pharyngitis, impetigo and pyoderma) to severe invasive infections and systemic 
manifestations (such as necrotizing fasciitis and streptococcal toxic shock syndrome). In 
addition, simple GAS infections can trigger autoimmune reactions in some patients 
leading to neurological disorders, glomerulonephritis, or acute rheumatic fever (3, 4). 
GAS encodes a large collection of virulence factors, which act to promote infections and 
pathologies by various means such as bacterial adherence and invasion, evasion of the 
host immune surveillance and nutrient acquisition (230). Due to the high morbidity 
associated with GAS related illnesses, this pathogen is ranked 9th among the world’s 
leading infectious agents (231). Recent global estimates suggest that every year about 
600 million GAS infections occur, accounting for ~ 600,000 deaths (232). The reported 
increase in antibiotic resistance, emergence of new strains, and absence of vaccine 
programs suggest that the disease burden inflicted by GAS is likely to rise (6, 233). 
 
GAS requires iron for growth and can retrieve the metal from heme (131). The cytolysins 
produced by GAS provide the pathogen with access to the host intracellular pool of 
hemoproteins. GAS proceeds with heme uptake using the streptococcal iron acquisition 
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(sia) operon: heme is extracted and captured on the bacterial surface by the streptococcal 
hemoproteins receptor (Shr), relayed to the streptococcal hemoprotein (Shp), and 
subsequently to the substrate binding protein, SiaA (HtsA). The SiaBC importer then 
internalizes the heme (32, 133-135, 186). Although heme is nutritionally beneficial, its 
pro-oxidant nature renders it hazardous in surplus quantities (85). We recently observed 
that exposure to sub-lethal heme concentrations elicits a global stress response in GAS 
(50). This observation underscores the harmful potential of heme. Heme toxicity seems 
particularly relevant to the patho-physiology of the -hemolytic pathogen, and could 
impose as a significant challenge for GAS growth during invasive infections. 
 
Heme-mediated cell injuries are primarily accredited to the coordinated iron element. The 
dynamic existence of iron in two redox and spin states within heme allows it to react with 
multiple biological entities including proteins, nucleic acids and lipids. This effect is 
exacerbated by the participation of iron in Fenton reactions, which lead to generation of 
radicals or reactive oxygen species (234). In addition to iron toxicity, the lipophilic nature 
of the protoporphyrin-ring (PPIX) is associated with photosensitivity and insertion of 
heme into membranes. This process was shown to undermine membrane permeability 
and further potentiates the release of free-heme from erythrocytes (235, 236). In 
mammalians, increased and persistent flux of free-heme in the vascular system is 
associated with significant inflammation and pathology (237). 
 
To manage heme toxicity, bacteria carefully control heme uptake according to cellular 
demands. In GAS for example, a metalloregulatory protein named MtsR, directly 
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represses the expression of the sia operon in the presence of iron (65). In addition to 
limiting heme uptake, bacteria employ various sequestration, degradation, and active 
efflux mechanisms. The export of heme excess and its role in protection against toxicity 
has been increasingly recognized in bacteria. The multiple-transferable-resistance 
(MtrCDE) efflux system from Neisseria gonorrhea which, expels hydrophobic 
antibacterial agents (238), also facilitate resistance to PPIX, heme, and other porphyrin-
based compounds. Inactivation of the mtrCDE pump resulted in increased gonococci 
sensitivity to porphyrins and metalloporphyrins, while overexpression of this system 
endowed cells with an increased tolerance to porphyrin based compounds (239). The E. 
coli MacAB pump is another example of an active exporter with broad specificity that 
contributes to heme tolerance. MacAB (with the TolC outer membrane channel protein) 
enables eneterotoxin secretion and confers resistance to macrolides (240, 241). In 
addition, MacAB-TolC serves as the major PPIX exporter in E. coli (242). 
 
In Gram-positive organisms, the archetype of an exporter that mediates heme tolerance in 
several bacteria including Bacillus anthracis and Lactococcus lactis was identified first in 
Staphylococcus aureus and named heme-regulated transporter (HrtAB) (94, 96, 243, 
244). Work performed in L. lactis suggested that this system exports heme directly from 
the membrane, acting to limit heme accumulation in this compartment (96, 245). The 
expression of the hrtAB genes is tightly regulated according to heme availability via the 
two-component system HssRS (in S. aureus and B. anthracis) or the heme-dependent 
repressor, HrtR (L. lactis) (94, 96, 246). The presence of the HrtAB transporter and the 
associated regulatory network bestows bacteria with elevated heme sensing and 
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resistance capacity. Studies in mouse infection model demonstrated that the HrtAB 
promoter in B. anthracis is induced in vivo, suggesting that the HrtAB transporter is 
recruited during infection, presumably to alleviate heme toxicity (94). Interestingly, while 
both species exhibit similar sensitivity to environmental heme, the loss of hrtA in B. 
anthracis has a more pronounced impact than in S. aureus, implying that heme sensing 
and/or detoxification by the HssRS and HrtAB systems are more effective in B. anthracis 
than in S. aureus. (94). The genome of Group B streptococcus (GBS) contains putative 
hrtAB homologs that are regulated by heme availability. However, contribution of these 
genes to heme efflux and tolerance in GBS has yet to be determined. In addition, GBS 
carries a regulon called porphyrin regulated efflux (pef) whose expression is controlled 
by PefR, a MarR-like repressor (95). Heme or PPIX allow for transcriptional activation 
of the pef regulon by relieving PefR binding to its operator. The pef regulon consists of at 
least two separate gene clusters (pefAB and peRCD) that encode two distinct transporters, 
pefAB and pefCD. Inactivation of the GBS pef transport system results in increased 
sensitivity to heme and intracellular buildup of heme and PPIX. Overexpression of these 
systems led to heme depletion and a defect in both respiratory metabolism and virulence 
(95). In Listeria monocytogenes, an ATP-dependent transporter, FrvA (Fur regulated 
virulence factor A), was implicated in heme export and protection from heme toxicity 
(247). Notably, the FrvA transporter is essential for the systemic infections in mice 
models. 
 
Mechanisms of heme tolerance are poorly understood in GAS. We recently identified a 
three-gene operon in GAS that shares significant similarity to the GBS pefRCD genes. 
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We demonstrated that these genes are up regulated in response to heme exposure and 
implicated the PefR homolog in heme sensing and regulation of the gene cluster (50). In 
this study, we set to determine the function of the pefCD genes in GAS physiology. 
 
5.2 Materials And Methods 
 
5.2.1 Bacterial strains and growth conditions 
Plasmids and strains used in this study are listed in Table 6 and the primers are described 
in Table 7. E. coli cells were used for cloning and propagation of plasmids. E. coli was 
grown aerobically in Luria-Bertani medium (BD) at 37 °C (pH 7.0 ). GAS was grown 
under static conditions in Falcon tubes or nephelometer flasks in THYB: Todd-Hewitt 
broth (TH broth, Difco laboratories) with 0.2% (weight/volume) yeast extract (BD). 
Growth was measured using a Klett-Summerson colorimeter (A filter) and / or by viable 
counting. In some cases, hemin chloride (Sigma) prepared in DMSO (0.035% final 
concentration, Fisher BioReagents) was added to the cultures. Antibiotics were used at 
the following concentrations: Spectinomycin at 100 g/ml for both E. coli and GAS, and 
kanamycin at 70 g/ml for E. coli and 300 g/ml for GAS. 
 
5.2.2 Nucleic acid methods.  
Chromosomal and plasmid DNA extraction and DNA manipulations including restriction 
digests, cloning, and DNA transformation were done according to the manufacturer’s 
recommendations and with standard protocols as previously described (248). Plasmid 
DNA was isolated from E. coli using the Wizard Plus SV mini-prep system (Promega). 
  
 
68 
DNA was subjected to restriction digestion (SpeI-HF® and or EcoRI of NEBL), and 
fragments were gel purified from agarose using S.N.A.P. UV-free gel purification kit 
(Invitrogen). The digested and gel purified fragments were ligated using T4 DNA ligase 
(Roche) to generate a recombinant construct. 
 
5.2.3 Construction of plasmids, GAS mutants and complementation strains:  
The pefC::pMZ1 mutant, ZE4951, was constructed in NZ131 background by Campbell 
insertion using plasmid pMZ1. Briefly, an internal 696 bp fragment from the pefC gene 
was amplified from NZ131 chromosome using ZE565 and ZE566 primers and ligated 
into the EcoRI site in pUC-Spec, which carries the spectinomycin resistance gene, aad9 
(249). The resulting plasmid, pMZ1, was introduced into NZ131 strain and 
spectinomycin resistant colonies were selected. The structure of the chromosomal 
pefC::pMZ1 mutation was verified by PCR and sequence analysis. For complementation 
analysis, a 4336 bp fragment spanning the pefRCD operon including the promoter region 
was amplified from NZ131 chromosome with ZE634 and ZE635 primers and ligated into 
the SpeI site of the shuttle vector, pKSM201 (250), which carries the kanamycin 
resistance gene aphA3, generating pANKITA5b. The plasmids pKSM201 (empty vector) 
and pANKITA5b were introduced into ZEM4951 strain by selection for spectinomycin 
and kanamycin resistance. 
 
5.2.4 Heme and doxorubicin sensitivity assay 
GAS sensitivity was tested using the Disc Diffusion method as previously described (50). 
Briefly, sterile 8.0 mm Whatman filter paper discs (with 1.2 mm width) were submerged 
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in 10 mM heme or 1.6 mM Doxorubicin (prepared in water) solutions, dried and 
impregnated onto THYA that was plated with 0.1 ml (OD600nm = 0.1) of overnight GAS 
culture. The plates were incubated at 37°C for 17 hours before the zone of clearance 
around the discs was measured. 
 
5.2.5 Determination of lipid peroxidation using TBARS assay 
Fresh THYB was inoculated with GAS cells collected from plates: the inocula consisted 
of cells grown overnight at 37°C on THYA and suspended in saline. Bacterial 
suspensions at OD600 = 0.5 were diluted 1:100 into fresh THYB, incubated at 37°C, and 
growth was monitored. Heme (1 μM) was added at the logarithmic phase of growth (~ 
60-70 Klett units) and samples (standardized according to cell density) were harvested by 
centrifugation (5000×g, 20 min at 4°C) at 30, 60, and 90 minutes post exposure. The cell 
pellets were washed and samples were prepared and analyzed for lipid peroxidation using 
OXI-TEK TBARS (Thiobarbituric Acid Reactive Substances) assay kit (ZeptoMatrix 
Corporation) as previously described (50). Sample absorbance at 532 nm was recorded 
using the DU 730 Life Science UV/vis spectrophotometer. The A532 nm obtained for the 
experimental samples were compared to a standard curve generated using the 
malondialdehyde (MDA) reagent supplied with the kit. 
 
5.2.6 DNA damage detection 
Fresh THYB medium was inoculated with GAS cells collected from THYA plates as 
described above. The cultures were treated with 5 μM heme at the logarithmic phase of 
growth (~ 60-70 Klett units) and samples (standardized according to cell density) were 
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harvested at 0, 30 and 90 minutes post exposure. Genomic DNA was extracted from the 
cell pellet using the ArchivePure DNA extraction kit (5 PRIME). DNA purity and 
concentration were determined and 0.5 μg of DNA samples were used to quantify the 
formation of apurinic/apyrimidinic (AP) sites using the DNA damage detection kit 
(PromoKine) per the manufacture instructions. Briefly, DNA (500 ng) was incubated 
with aldehyde reactive probe containing biotin tag (ARP) solution for 1 hour at 37 °C. 
Glycogen and TE buffer were added to the solution, the DNA was allowed to precipitate 
at -20°C for 10 min and then collected by centrifugation at 13,000 rpm for 10 minutes at 
4°C. The pellet of the biotin-tagged DNA was washed with 70% ethanol, air-dried, 
resuspended in 1ml of TE buffer. The DNA samples (60 l) were added to 96 well 
ELISA plate and incubated overnight at room temperature with DNA binding solution. 
The signal was developed after incubation with horseradish peroxidase (HRP)-
streptavidin solution and developer. The signal intensity was quantified spectroscopically 
at 650 nm. A standard plot depicting the absorbance at 650 nm as a function of the 
number of standard AP sites of standard solution (0, 8, 16, 24, 32, and 40 ARP sites/105 
bp solution) was used to determine the number of AP sites /105 bp DNA fragment in 
experimental samples. As a positive control for AP site formation in GAS cells, we used 
cells exposed to 10 mM H2O2 solution for 1 hour at 37°C followed by genomic DNA 
extraction, labeling, and detection similar to standards and experimental samples (data 
not shown). 
5.2.7 Determination of intracellular hemin content 
Fresh THYB medium was inoculated with GAS cells collected from plates as described 
above. The cultures were treated with 3 μM heme at the logarithmic phase of growth (60-
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70 Klett units) and samples (standardized according to cell density) were collected 90 
minutes post exposure by centrifugation (8000×g for 20 min at 4 °C). The cell pellet was 
washed 5 times (10 ml phosphate buffered saline, pH 7.0 each), resuspended in 2 ml of 
DMSO, and subjected to sonication (20 % amplitude for 30 sec.). Heme content in the 
cell lysate was determined using the procedure described by Lombardo et al with small 
modifications (251). Briefly, 4 ml of experimental samples along with hemin standard 
solutions (0-5 μM, in DMSO) were subjected to acidified chloroform extraction as 
follows: addition of 2 ml of 50 mM glycine buffer, pH 2.0 then 0.1 ml of 4N HCl (pH 
2.0), 0.2 ml of 5M NaCl (pH 2.0) and chloroform (2 ml) followed by vigorous mixing for 
10sec (6 times). The reactions were incubated at room temperature for 1 minute and the 
absorbance by the organic phase was then determined. The absorbance at 388, 450 and 
330 nm were recorded and fed into the correction equation Ac = 2×A388−(A450+A330). The 
plot of Ac corrected for standard heme concentrations was used to extrapolate the hemin 
concentration in experimental samples. 
 
5.3 Results 
 
5.3.1 The pefCD genes encode a conserved Class-1 ABC exporter 
We recently reported the transcriptional activation of a 3-gene cluster  (MGAS5005 
spy_0195, 0196, and 0197) ensuing GAS exposure to environmental heme. We named 
these GAS genes as pefRCD based on similarity in genetic organization, primary 
sequence, and regulation to the previously described pefRCD operon in GBS (50, 95) 
(Figure 21A). Here, our analysis showed that the pefRCD genes are highly conserved 
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among GAS strains exhibiting 100% identity for PefR, 98% identity for PefC, and 99% 
identity for PefD protein (for all 20 strains in the database). The pefCD genes are 
annotated in GAS genome as the subunits of a putative multi-drug resistance (MDR) 
system. Sequence analysis indicated that the pefCD genes code for the two subunits of a 
heteroligomeric ATP-dependent exporter. Both ORFs contain, at the N terminus, an 
integral membrane (IM) permease domain from the superfamily of ATP binding cassettes 
fused to an ATP-hydrolyzing domain (ABC, also referred to as the nucleotide binding 
domain) (Figure 21B). This domain organization is of the Class-1 ABC-type transporter 
family (252). This transporter class is comprised of systems with fused IM and ABC 
domains and contains the vast majority of ABC-type export systems (252). Our recent 
BLAST analysis against the transporter classification (TC) database 
(http://www.tcdb.org) (253) revealed that the PefCD proteins consists of a transporter 
from the drug exporter-4 sub class (3.A.1.135). Importantly, this analysis revealed that 
PefCD exporter is identical to a previously described transporter from the GAS strain 
JRS4, named Rsc (regulated by stress and Cov) after its regulation by the response 
regulator CovR (254). The substrate(s) of the Rsc system was not identified but the 
transporter was found to be required for bacterial growth at high temperature. The nearest 
relatives of the PefCD (RscAB) proteins are the components of the MDR transporters, 
SatAB of S. suis (255), PatAB from S. pneumonia (256), and LmrCD (aka YdaG and 
YdbA) from L. lactis (257). For simplicity we continue in this manuscript to refer to the 
GAS exporter as the PefCD system. Further in-silico analysis performed on genomes of 
streptococci identified putative homologs of the pefRCD gene cluster in S. equi, S. uberis, 
S. suis, and S. iniae (258-262). A high degree of conservation in genetic organization and 
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sequence exhibiting 54% amino acid similarity for the PefR, 60% for the PefC, and 64% 
for the PefD protein among all the candidates tested by ClastalW pairwise alignment tool 
(263), (Figure 21A). 
 
5.3.2 Inactivation of pefCD resulted in a growth phenotype and hypersensitivity 
to heme and doxorubicin. 
In order to gain insight into the role of the pefCD genes in GAS physiology, we created a 
polar mutation in pefC by insertion inactivation (ZE4951 strain) in the background of the 
wild type strain, NZ131 (Table 6 and Figure 22A). For complementation of pefCD polar 
mutation, we cloned the pefRCD operon with its native promoter into a shuttle vector 
(pKSM201). E. coli cells harboring the plasmid carrying the GAS pefRCD operon 
(pANKITA5b) did not exhibit any growth phenotype. However, despite our multiple 
attempts, we failed to create a sub clone that expresses only the pefCD genes (under the 
pef promoter). We therefore used the entire pefRCD operon (carried by pANKITA5b) to 
complement the ZE4951 mutant. Analysis of ZE4951 growth in THYB media 
demonstrated that inactivation of the pef system resulted in a pronounced phenotype; the 
mutant cells grew slower and reached the stationary phase of growth at a lower cell 
density in comparison to the isogenic NZ131 wild type strain (Figure 22B). In addition, 
cell viability of the mutant strain was significantly reduced during overnight incubation in 
stationary phase (data not shown). The growth defect of the ZE4951 mutant was reversed 
in the presence the pefRCD genes expressed in trans (pANKITA5b) but not in the 
presence of an empty shuttle vector (pKSM201, Figure 22). This analysis suggests that 
the pefCD genes are required for optimal GAS growth in standard laboratory medium. 
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When tested for heme sensitivity, the ZE4951 mutant strain exhibited a larger zone of 
clearance around a heme-submerged disc compared with the wild type strain (Table 8). 
The mutant sensitivity to heme was restored to the wild type level when complemented in 
trans with the pefRCD genes, but not in the presence of the control plasmid. These 
observations supported the hypothesis that PefCD consists an efflux system that extrudes 
heme or heme-related toxic metabolites. While some exporters are selective for a given 
substrate, many are able to expel a range of structurally unrelated molecules (93, 252). 
Examining the growth of the mutant strain around discs containing the anthracyclic 
compound, doxorubicin, revealed increased sensitivity compared with the parent strain 
(Table 8). As with the sensitivity to heme, the doxorubicin hypersensitivity phenotype 
was reversed when the pefRCD genes were supplied in trans (Table 8). Heme and 
doxorubicin are structurally dissimilar; these data are consistent with the in silico analysis 
described above and imply that PefCD is an exporter with a broad substrate specificity. 
 
5.3.3 Inactivation of the pefCD system is associated with elevated levels of 
heme-induced damage to cellular constituents 
In order to uncover why the loss of the pefCD genes leads to reduced heme tolerance in 
GAS, we investigated the impact of heme on GAS cellular components in the wild type 
and mutant strains. In a recent study we demonstrated that exposure to low heme 
concentration was sufficient to damage the lipids in GAS envelope (50). Oxidized lipids 
react with a thiobarbituric acid (TBA) reagent to form adducts (named TBARS) that can 
be monitored by spectroscopic methods and quantify with a standard curve (50, 201). We 
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compared the time course of TBARS formation between the wild type and mutant strain 
after the addition of 1 μM heme into the culture (Figure 23). Analysis of samples 
collected 30 minutes post exposure revealed that the ZE4951 mutant exhibited higher 
level of lipid damage than the wild type strain (3 versus 1.5 nmol/ml TBRAS in the 
mutant and wild type strain respectively). Complementation of the pefC mutation with 
the pefRCD genes resulted in a significantly lower level of TBARS formation, in 
comparison to mutant cells harboring the negative control plasmid (0.97 and 2.49 
nmol/ml respectively). Interestingly, the TBARS levels in the complemented mutant 
strain were reduced over time (from 0.98 to 0.38 nmol/ml in the 30 and 90 min samples 
respectively), while they remained approximately the same in the wild type, mutant, and 
the mutant cells harboring the control plasmid. Together these observations imply that the 
PefCD system defends GAS from heme-induced lipid damage and suggest that the 
expression of pefRCD genes under our experimental conditions may be limiting in the 
wild type strain. 
 
Studies performed with eukaryotic systems showed that heme could harm nucleic acids 
(264). We asked if environmental heme can damage GAS genome and if the pef system 
offers protection from this harm. The repair of chemically altered bases (due to oxidation, 
deamination or alkylation) in the DNA is often mediated by repair mechanisms that 
involve the formation apurinic/apyrimidinic (AP) sites. Therefore, the amount of AP sites 
serves as a good indicator for DNA damage and repair. To quantitate the formation of AP 
sites in GAS chromosome, we used a reagent (ARP) that reacts specifically with the 
aldehyde group in the open ring form of the AP sites (265). Chromosomal DNA was 
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extracted from culture samples that were harvested at different time points and was 
allowed to react with ARP reagent. The formation of AP sites was detected by ELISA 
and quantified using a standard curve (Figure 24). Analysis of chromosomal DNA from 
culture samples of the wild type strain collected 30 minutes after the addition of heme 
revealed about 90% increase in the number of AP sites compared to the background level 
(11 and 5.8 AP sites per 105 bp respectively). The AP sites level was reduced over time, 
but remained 40% above the background (8 AP sites per 105 bp) in the samples collected 
90 minutes after treatment. Interestingly, in pefC mutant the background level of AP sites 
was about twice as high compared with the wild type strain (11.5 AP sites per 105 bp). 
Heme exposures resulted in a transient 117% increase in the number of AP sites, which 
was reduced to background level within 60 minutes (25 and 11.5 AP sites per 105 bp in 
the 30 and 90 minutes respectively). The high AP levels observed in the mutant strain 
were complemented to those observed in the wild type strain by the pefRCD genes 
expressed from a plasmid in all samples. The levels of AP sites in the mutant strain 
carrying the empty vector were comparable to that of the mutant strain alone. These 
experiments indicate that environmental heme led to DNA damage in GAS and that the 
pefCD genes offered protection from DNA damage during growth in laboratory medium 
as well as in medium containing externally added heme. In addition, our data highlights 
the presence of DNA repair mechanisms in GAS. 
 
5.3.4 The pefCD prevents cellular heme accumulation 
One interpretation of the experiments described above is that following the addition of 
heme to the culture medium GAS cells absorb it in surplus amounts; in the absence of a 
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functional PefCD system, the bacterium accumulates heme or heme-related metabolites 
that damage the cell constituents. To directly test this hypothesis, we examined the 
cellular heme content by the acidified chloroform extraction method (251) described in 
the material and methods (Figure 25). Culture samples of equal cell density were 
collected 90 minutes after the addition of 3 μM heme to the medium and the cells were 
washed extensively to remove surface bound heme prior to heme extraction. The 
presence of heme in the organic phase of the cell extracts was examined by spectroscopic 
analysis and the concentration of the extracted heme from each sample was extrapolated 
from a standard curve (Figure 25B and 25D). We extracted in these experiments about 
30% more heme from the pefC mutant in comparison to the wild type strain. The heme 
concentration obtained from cells of the pefC mutant complemented with the pefRCD 
genes, was 7% lower than that extracted from the wild type cells. On the other hand, the 
presence of the empty vector did not have a significant impact on the heme concentration 
in the extract from the pefC mutant. Therefore, the PefC accumulates more heme then the 
wild type strain. This observation suggets that the PefCD system expels surplus heme 
from GAS cells. 
 
5.4 Discussion 
 
Heme is an important nutrient for the β-hemolytic GAS, which uses it in order to obtain 
iron within the host environment (131). Despite its nutritional value, heme is a harmful 
molecule, damaging to GAS envelope even in low concentrations (50). In the current 
study, we investigated how GAS manages the toxic challenges imposed by environmental 
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heme. We recently identified a 3-gene operon that was induced by heme and named it 
after the pefRCD system in GBS (50, 95). Following up on our initial observations, we 
carried out a functional characterization of the pefCD genes in the GAS strain, NZ131. 
We established that they play an important role in heme tolerance; defending GAS 
membrane and chromosome from the toxic effects of heme stress and prevents heme 
accumulation in the bacterial cells. This is the first heme tolerance pathway to be 
described in GAS. 
 
To examine the role of the pefCD genes in GAS, we created a polar mutation in pefC, 
which we then supplemented with the pefRCD expressed from a plasmid. All of the 
observed phenotypes of the pefC mutant were effectively complemented, indicating that 
under our experimental conditions, the PefCD proteins were expressed in trans at 
sufficient levels despite the presence of the putative repressor, pefR, on the 
complementation plasmid. Our failed attempts to clone pefCD under the native pef 
promoter in the absence of pefR raises the possibility that the constitutive expression of 
the pefCD genes is detrimental to E. coli. Toxicity of membrane proteins when 
overexpressed or of proteins expressed in heterologous host is not uncommon. A similar 
problem was reported for the related SatAB system of S. suis (255). 
 
Examining the phenotype of the pefC mutant and the complemented strain showed that 
the loss of the PefCD system led to increased sensitivity to heme and doxorubicin (Table 
8). This observation is consistent with the bioinformatics analysis that revealed 
significant similarity among PefCD proteins and the confirmed MDR transporters SatAB, 
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PatAB, and LmrCD from S. suis, S. pneumoniae and L. lactis respectively (255, 257, 
266). Together, these observations imply that the PefCD proteins consist of a MDR 
transporter that expels doxorubicin and heme or heme related metabolites. Our additional 
findings demonstrated that GAS accumulates heme in the absence of a functional PefCD 
transporter (Figure 25), strongly implicating heme as a substrate of the pefCD system. 
The pefC mutant exhibited growth attenuation in THYB (Figure 22B). THYB contains 
infusions of brain and heart tissues. Therefore, the mutant growth phenotype might have 
resulted from increased sensitivity to the heme that is already present in the medium. 
Alternatively or in addition, PefCD may help in the clearance of other toxic molecules 
that are generated during growth. Interestingly, a previous study performed in the JRS4 
strain revealed that the pefC (rscA) gene is induced at low pH and by heat stress and that 
a pefC mutant could not grow at 40 °C. The growth phenotype at a high temperature 
raised the possibility that the pefCD proteins export molecules that harm the membrane 
structure and fluidity (254). Heme could be such a molecule, since it is known to 
penetrate membranes and undermine the membrane permeability (245, 267). 
Alternatively, other compounds exported by PefCD may be responsible for this 
phenotype. 
 
We previously reported that the addition of 4 μM heme to the culture medium produced 
oxidative damage in the envelope of the invasive MGAS5005 strain (50). In this work, 
we made similar observations with the nephritogenic NZ131, and showed that exposure 
to 1 μM heme led to noticeable levels of lipid peroxidation (Figure 23B). Moreover, we 
showed for the first time that externally added heme (5 μM) is also damaging to GAS 
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chromosome (Figure 24B). Together, these observations highlight the destructive impact 
of environmental heme on GAS cellular components even at relatively low 
concentrations. A number of observations demonstrate the importance of the PefCD 
system in heme detoxification and suggest a positive correlation between the expression 
of pefCD system and detoxification capacity: 1) The pefC mutant experienced more lipid 
and DNA damage comparing with the wild type strain after heme treatment (Figure 23B 
and 24B). 2) The level of lipid peroxidation in the wild type strain remained constant for 
30-90 minutes post treatment, while it was reduced over time in the complemented strain 
(Figure 23B). 3) More AP sites were detected in the chromosome of the pefC mutant 
comparing to the wild type strain even in the absence of externally added heme. 4) Heme 
begins to accumulate in the mutant cells after its addition to the growth medium (Figure 
25D). The pef regulon in GBS is induced by levels of heme that are lower than those 
required to fully activate the putative HrtAB transporter; it was therefore suggested that 
the Pef exporters allow for adjustments in small variations in heme and PPIX 
concentrations under different physiological conditions while the Hrt exporter may be 
needed to defend GBS against higher heme concentrations (95).  Here, we established 
that the PefCD system in GAS is responsive to low levels of environmental heme (1-5 
μM) and participate in the detoxification process. We did not identify HrtAB homologues 
in GAS, but it is possible that additional transporter(s) in GAS are recruited at higher 
heme concentrations. 
 
GAS is a versatile pathogen that exhibits wide tissue tropism and adaptability that 
enables it to inhibit not only the epithelia of the skin and mucous membranes, but also to 
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flourish within soft tissues, the lymphatic system, and the blood (4). Therefore, 
depending on the nature and stages of infection, GAS is expected to confront a wide 
spectrum of heme concentrations, ranging from low amounts (e.g., during simple skin or 
mucosal infection) to very high concentrations (such as during invasive infections 
associated with significant erythrocyte lysis and tissue destruction). Furthermore, heme 
tolerance varies among GAS isolates with highly invasive strains such as MGAS5005 
showing higher resistance (Heme MIC = 50 μM) than strains that are typically associated 
with local infections such as NZ131 (MIC = 10 μM) (50). We propose that the PefRCD 
represent a fundamental heme defense pathway that is shared by all GAS strains, 
safeguarding the organism against environmental heme. Highly invasive strains may 
carry additional pathway(s) that might confer increased resistance. 
 
The role of active export in the management of heme (and other porphyrins) levels and 
toxicity in bacterial systems is not fully appreciated and only few systems have been 
described up to date. Two systems were identified in Gram-negative bacteria 
(MacAB/TolC and MtrCDE for E. coli and N. gonorrhoeae, respectively) (239, 242, 
268). Both exporters consist of cytoplasmic transporters that connect via a membrane 
fusion protein to an outer membrane channel/tunnel protein. Both cytoplasmic 
transporters are MDR systems that export a number of compounds in addition to heme 
and/or porphyrins. However, MacAB is an ATP-type transporter while MtrC belongs to 
the Resistance/Nodulation/Division (RND) family of transporters, which uses the proton 
motive force for energy-dependent export. In Gram-positive bacteria, four types of 
energy dependent exporters used for heme and/or PPIX detoxification were described 
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(Figure 26). Intriguingly, HrtAB, which was first identified in S. aureus (244), belongs to 
the MacAB family of ABC-type efflux carriers. In this family of ABC transporters, the 
membrane permease (IM) and the ATPase (ABC) domains are encoded by separate 
polypeptides (Class 3) (252). HrtAB mediates heme tolerance in a number of Gram-
positive bacteria. It was shown to pump heme directly out of the membrane compartment 
in L. lactis (245) and it is likely that it functions in a similar manner in the other Gram-
positive species. In L. monocytogenes, a P-Type ATPase, that displays homology to 
bacterial heavy-metal transporting ATPases, confers resistance to heme and hemoglobin 
(247). The two other types of transporters were described first in GBS: PefAB 
(antiporter) belongs to the MFS family that relies on the proton motive force and PefCD, 
which is a Class I, ABC-type transporters (95). In this study, we showed that the GAS 
PefCD system contributes to tolerance against both heme and doxorubicin. The 
involvement of the other transporters from Gram-positive bacteria in resistance to 
compounds other than porphyrins was not examined. We established significant 
orthology between the GBS PefCD and the system encoded by GAS. Moreover, our in 
silico analysis suggests that the previously described SatAB transporter from S. suis is an 
orthologous system and that a pefRCD–like operon is also found in the members of the 
pyogenic streptococci. In GBS, the PefCD proteins export heme and PPIX (95). Our 
work here illustrates that this transporter in GAS exports heme and doxorubicin. The S. 
suis, SatAB, is a narrow-spectrum fluoroquinolone exporter (norfloxacin and 
ciprofloxacin) (255). It will be interesting to find out whether the PefCD system is a 
MDR transporter that has heme as one of its substrates or if it has evolved distinct 
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substrate specificities among various species reflecting differences in ecological niches 
and lifestyle.  
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APPENDIX 
Appendix A: Tables 
Table 1: Strains and plasmids used in chapter 2 
Name Description Reference 
Strains 
     E.coli  Top10 
    E.coli  BL21 Star 
 
 
 
  
Host for pZZ2 propagation 
Host for pZZ2 expression  
 
 
Invitrogen 
Invitrogen 
 
Plasmids 
           
           pET101/D-TOPO  
           pOM101 
           pZZ2 
 
 
Directional TOPO® TA cloning 
vector  
Expresses Shp-His tag from PT7 
Expresses HupZ-His tag from 
PT7 
 
 
Invitrogen 
 (135) 
This study 
 
Table 2: Crystallographic data collection and refinement statistics 
 
PDB Code 
Space group 
4NU4 
P1 
Cell Dimensions  
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a (Å) 
b (Å) 
c (Å) 
 () 
 () 
 () 
41.82 
61.18 
61.35 
78.59 
86.76 
80.07 
Molecules/asymmetric unit 4 
Resolution range 50.0 – 2.0 
Total observations 142558 
Unique reflections 39089 
Completeness 98.2 (97.7)a 
<I/(I)> 13.6 (7.7) 
Rsym (%) 9.9 (37.7) 
Refinement resolution range 50 – 2.0 
Rcryst (%)
 17.0 
Rfree (%) 21.7 
Number of solvent 270 
Mean B-factor (Å2) 24.7 
RMS deviations from ideality  
Bond length (Å) 0.03 
Angles () 2.2 
aValues in parentheses are given for the highest resolution shell (2.00-2.03 Å) 
 
  
 
104 
Table 3: Strains used in chapter 3 
 
Name Description References 
Strains    
MGAS5005 GAS (M1), isolated from cerebrospinal fluid (199) 
NZ131 GAS (M49) isolated from acute post-
glomerulonephritis infection 
(197) 
GA01398 GAS (M11).   GA-EIP* 
GA06439 GAS (M114)  GA-EIP* 
GA02581 GAS (M1)  GA-EIP* 
GA02582 GAS (M1)  GA-EIP* 
GA10156 GAS (M75)  GA-EIP* 
COL (MRSA) S. aureus, clinical specimen isolated from 
operating theater in England 
(269) 
E. cloni® 10G Host for pAJS11 propagation and expression Lucigen 
 
Plasmids 
  
pRham™ N-
His 
Protein expression vector, KanR, expressed from 
rhaPBAD 
Lucigen 
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pAJS11 Expresses N-Terminal His-tag PefR, KanR  This study 
*Georgia Emerging Infections Program (GA-EIP) 
 
Table 4: Primers used in chapter 3 
 
 
Target 
 
PCR primers 
 
Sequence (5'-3') 
 
   
pefR ORF ZE515 CATCATCACCACCATCACTCACAAGTG
ATAGGTGATTTACG 
 
ZE516 GTGGCGGCCGCTCTATTAAGCATCGTTG
TCTCCTTTATAA 
Ppef ZE561 AAGGCGTTCCCAAGAGAGCTAG 
 ZE562 CCTTGAGGACCTGCTAGATGCTCTAC 
pefR  ZE569 CAATGTGATGCCTTCCCAAG 
 ZE570 CGCTGTCAGCAACTCTTC 
pefC  ZE571 CCTCATCATGGGTTTGGTG 
 ZE572 ACGCCACGGAGATTTTCC 
rpsL  ZE581 CAGATTCACCAGCTTTGAAC 
 ZE582 CAACACGAGTAGCAACG 
prsA prsA-M1-RT-L GGGCAGACTTTGCAGCTATTG 
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 prsA-M1-RT-R TCGCCTGAGTCAAACGTATAGG 
clpL clpL-M1-RT-L TGGCTTGAGCTAAACCTTCA  
 clpL-M1-RT-R CTTGGCACGACGAACTAAAA 
opuAA opuAA-M1-RT-L TGATTTGCAAGACAGCATGA 
 opuAA-M1-RT-L CATCAAAGCAATCCGATCAC 
endoS endoS-M1-RT-L CTCGGTCAATAGCGTAGGAGAAG 
 endoS-M1-RT-L GCGTGCCGAACGGTATG 
ptsA ptsA-M1-RT-L TTTTTTAAAACCAGGCGAAGC 
 ptsA-M1-RT-L TTGTCTCAGGGACCAAATCC 
sagA sagA-M1-RT-L GCTACTAGTGTAGCTGAAACAACTCAA 
 sagA-M1-RT-L AGCAACAAGTAGTACAGCAGCAA 
spt7R spt7R-M1-RT-L TCATTTGCGGCTGAAATAATAATG 
 spt7R-M1-RT-L  GCAATGGGATTCAATTTTTGGA 
slo slo-M1-RT-L TTGTTGAGGATAATGTAAGAATGTTTA
G 
 slo-M1-RT-R TCCTGGCTTGCAACTGATTG 
fasC fasC-M1-RT-L TGCGCACAAATTATGAAATATCTTC 
 fasC-M1-RT-R GAGCTTCAAGCAATTTGGAATTC 
mtsA mtsA-M1-RT-L TGAGGGTCTTGACCGATTG 
 mtsA-M1-RT-R AAGTCGTGGCAACCAATTC 
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Table 5: Bacteriostatic effect of heme 
 
Straina 
Agar dilution 
(μM) 
Broth dilution 
(μM) 
Disc diffusion 
(mm) 
NZ131 (M49) 10 10 9 
GA01398 (M11) 20 30 1.25 
GA06439 (M114) 20 30 6.75 
GA02581 (M1) 20 50 6 
GA02582 (M1) 15 50 4.75 
GA10156 (M75) 20 30 4.5 
MGAS5005 (M1) 20 50 5.5 
S. aureus (control) 260 80 4.25 
 
The minimal heme concentration that inhibits bacterial growth (MIC) was determined by 
the methods of agar dilution and broth macrodilution. The growth inhibitory effect of 
heme is also expressed as the clearance zone around heme impregnate discs (10 mM). 
See material and methods for details. Data are representative of two independent 
replicates.  
a GAS M type (if available) is indicated in parentheses 
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Table 6: List of bacterial strains and plasmids used in chapter 4. 
 
Strain name Characteristics References 
S. pyogenes   
NZ131 M49 serotype isolated from 
acute post-
glomerulonephritis 
infection 
(197) 
ZE4951 NZ131 derivative with 
pefC::pMZ1 mutation 
This study 
ZE4951/pANKITA5b ZEM4951 strain 
complemented with pefRCD 
locus expressed from 
plasmid pANKITA5b 
This study 
ZE4951/pKSM201 ZEM4951 strain harboring 
the pKSM201 vector 
This study 
E. coli   
DH5α hsdR17 ecA gyrA endA1 
relA1 
(270) 
Plasmids   
pMZ1 pUC-Spec derivative 
containing pefC internal 
fragment and the spec  
This study 
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resistance gene aad9 
pKSM201 Shuttle vector containing 
the kanamycin resistance 
gene aphA3 
(250) 
pANKITA5b pKSM201 derivative 
carrying the pefRCD genes 
This study 
 
 
Table 7: List of primers used in chapter 4. 
 
 
Table 8: Determination of heme and doxorubicin sensitivity by disc diffusion assay 
Primers 
name 
(Target) 
Restriction 
site 
Sequence (5’-3’) Source 
ZE565 
(pefC) 
EcoR1 GGGGAATTCTTATGGTGGGTCATTGTTG This study 
ZE566 
(pefC) 
EcoR1 AATGAATTCTAAGCGAGGGATGAGCTGT
G 
This study 
ZE634 
(pefRCD) 
SpeI AAGGACTAGTGGTCTTGGCTAATAAGGC
G 
This study 
ZE635 
(pefRCD) 
SpeI AGGGACTAGTTTGGGATTCATGTTAGCG
AG 
This study 
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Strain Name Zone of clearance (mm) 
 
Heme Doxorubicin 
WT (NZ131) 11.8±1.37 16 
Mutant (ZE4951) 15.8±1.53a 23±1.25c 
Complement (ZE4951/pANKITA5b) 9±0.23 17±0.19 
Control (ZE4951/pKSM201) 13±0.31b 22±1.27d 
 
The letters a, b, c, and d represent P values of statistical significance at 0.05 levels of 
significance calculated using student t-test (of equal variance). The statistical significance 
was evaluated by comparing WT with Mutant & Complement with Control data set. 
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Appendix B: Figures 
 
FIGURE 1. 
 
 
 
 
Figure 1: Iron homeostasis. The fate of the acquired iron in the human body depends 
upon the physiological needs and stimuli resulting in transfer or storage of the metal (see 
text for details). This figure is adapted from (271). 
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FIGURE 2. 
 
Figure 2: The structure of porphyrin-heme. The B form of heme (Fe+2-PPIX) or hemin 
(Fe+3-PPIX) is a macrocyclic compound that consists of four tetrapyrrole rings (depicted 
as A, B, C, and D) held together by four methine bridges (α, β, γ, and δ). The nitrogen 
atoms of tetrapyrrole can coordinate metal iron that can take part in various biochemical 
reactions. 
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FIGURE 3. 
 
 
Figure 3: Spectral features of heme-porphyrin. A typical UV-visible spectra for PPIX, 
free heme, and heme bound protein (PefR, from GAS). 
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FIGURE 4. 
 
 
Figure 4: Catalytic intermediates of heme degradation by HO-1 The regiospecific 
degradation of ferric heme (which absorbs at the Soret region) involves oxygenation 
leading to formation of transient and highly unstable ferrous-hydroperoxyheme, which 
self-stabilizes by hydroxylation reaction on the edge of a tetrapyrrole. The hydroxylated 
ferric heme after undergoing second oxygenation reaction leads to release of CO and 
formation of ferrous-verdoheme. The verdoheme upon final oxygenation yields ferric 
biliverdin with the opening of macrocyclic structure. Ferric biliverdin through gain of 
protons releases iron and produces a chromophore biliverdin (which absorbs between 640 
to 680 nm). 
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FIGURE 5. 
 
 
Figure 5: Heme degradation pathway catalyzed by HO-1 (272). 
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FIGURE 6. 
 
 
Figure 6: HupZ is a heme binding protein. Counter-clockwise: A. SDS-PAGE 
showing purified recombinant HupZ next to molecular markers. B. UV-visible absorption 
spectrum of 10 M HupZ as purified from E. coli and the heme-bound form (heme-
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HupZ) in SPB. The UV-visible absorption spectrum of 5 M heme is included. A sample 
containing only SPB was used as a blank. C. UV-visible absorption spectrum of HupZ as 
purified (in SPB) from E. coli grown in the presence of 5-aminolevulinic acid. The FPLC 
purified fraction is documented in inset. D. Differential absorption spectroscopy of heme-
HupZ complex. Increasing amounts of heme were added at final concentrations of 1, 2, 4, 
6, 10, 12, and 14 M to both the blank and apo-HupZ (10 M). The insert shows the 
stoichiometry of heme binding to HupZ. The changes in absorbance at 414 nm were 
plotted against heme concentration, defining a 1:1 stoichiometry with tight binding. The 
data are representative of at least two independent spectroscopic analyses. 
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FIGURE 7 
 
Figure 7: Heme degradation by HupZ. A. Heme degradation in the presence of CPR 
and NADPH. UV-Visible absorption spectra were recoded before and at 10, 20, 30, 40, 
50 and 60 min after the addition of 250 μM NADPH to 10 M Holo-HupZ and 0.4 M 
CPR in SPB. SPB containing all reaction components other than HupZ and NADPH was 
used as a blank. B. Heme degradation in the presence of CPR and NADPH regeneration 
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system. The same as in A, except that the reaction contained 100 μM NADPH, 6.5 mM 
glucose-6-phosphate, and 1 unit of glucose-6-phosphate dehydrogenase as NADPH 
regeneration system. UV-Visible absorption spectra were recoded before and after the 
addition of NADPH, at 10 min intervals for 1 h, and then every 60 min for additional 5 h. 
C. The spectral changes insert demonstrates the changes in absorbance at 414 and at 660 
nm over time for every hour. Catalase (2 μM) was included in all of the reactions. The 
data are representative of at least two independent spectroscopic analyses. D. Control 
reactions for HupZ heme degradation. For Shp control, 20 μM holoShp was incubated 
with 0.4 μM CPR, 500 μM NADPH and 2 μM catalase in SPB (pH 7.4). Spectral changes 
were recorded at 25 °C for 60 min. For free heme control: 10 μM of hemin chloride was 
incubated with 0.4 μM CPR, 2 μM catalase and 100 μM of NADPH with regeneration 
system in SPB (pH 7.4). Spectral changes were monitored every 60 min for 6 h at 25 °C.  
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FIGURE 8. 
 
 
Figure 8: Evaluation of heme degradation by HupZ using FNR-Fdx as reducing 
equivalent. UV-visible absorption spectra were recoded before and at 10, 20, 30, 50 and 
60 min after the addition of 500 μM NADPH to 20 μM Holo-HupZ, 10 μM spinach Fdx, 
0.1 unit/mL spinach FNR and 2 μM catalase, in 1 mL SPB. The reaction spectra were 
recorded using SPB as blank. 
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FIGURE 9. 
 
 
 
Figure 9: Differential absorption spectra of holoHupZ reaction in the presence of 
myoglobin. Myoglobin (4 M) was added to a sample containing holoHupZ (5 M), 0.4 
M CPR and 2 M catalase in SPB. The spectra were recorded before and after the 
addition of 500 M NADPH at 30 s intervals for 16 min. SPB containing all reaction 
components other than myoglobin and NADPH was used as a blank. The control reaction 
was carried out in a similar manner, except without HupZ. The insert shows the 
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absorption changes at 410 (experiment and control) and 420 (experiment) nm over time. 
The data are representative of at least two independent spectroscopic analyses. 
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FIGURE 10. 
 
 
Figure 10: Differential absorption spectra of holoHupZ reaction in the presence of 
ferrozine. A. Heme degradation by holoHupZ (20 M) was carried out in SPB 
containing CPR (0.4 M), 200 M NADPH with regeneration system, ferrozine (1 mM), 
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and catalase (2 M).  UV-visible absorption spectra were recorded before and 12, 18, 30, 
42, 48, 60 min after the addition of NADPH and then every 60 min for 5 h, and an 
additional time point was taken after 22 h. SPB containing all the reaction components 
other than holoHupZ and NADPH was used as a blank. As a control, heme (20 M) was 
incubated in sample buffer with ferrozine and catalase. B. The absorbance changes over 
time at 414 (heme degradation) and 564 (iron-ferrozine complex) nm in the sample and 
control reactions (for free hemin) at 410 nm were recorded. The data are representative of 
at least two independent spectroscopic analyses. C. Titration of ferrozine with ferrous 
iron. 250 μM of ferrozine was incubated with an increasing concentration of FeSO4 (0.1, 
0.5, 1, 5, 10, 20, and 50 μM) solution in SPB in a 1 mL final volume and spectral changes 
were recorded. The standard curve was obtained from plotting the increase in absorbance 
at 564 nm against the ferrous iron concentration. 
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FIGURE 11. 
 
 
 
Figure 11: Crystal structure of HupZ. A. Structure of HupZ homodimer. The two 
monomers are colored in red and green. B. The split barrel fold of HupZ monomer 
with the three -helices and six β-strands labeled. C. Superposition of HupZ (red) 
with HugZ (yellow). The heme binds to the extended C-terminal end of HugZ, which 
appears to be truncated in HupZ. His245 near the C-terminal end is involved in heme-Fe 
coordination and conserved across other split barrel heme oxygenases. The Arg166 
important for enzymatic activity of HugZ is substituted by glycine on secondary structure 
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matching. Heme, Arg166, His245 and azide from the HugZ structure are shown in stick 
representation and colored by element type in C and D. D. Superimposed structures of 
HupZ (red) and ChuZ (cyan). ChuZ binds two heme moieties. The first heme binds at 
the flexible C-terminal end of the split barrel domain similar to HugZ with similar 
coordination, while the second heme binds at the N-terminal domain, which is absent in 
HupZ.  
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FIGURE 12. 
 
 
Figure 12: Phylogenetic tree of HupZ with other heme degrading enzymes.  The tree 
was obtained from multiple sequence alignment in ClustalW (273). We used neighbor-
joining method for tree construction and bootstrap analysis (parameter set at 1000 
resampling) preformed using MEGA win-5.21 software (274). The locus tag or the 
accession number for each protein used in the sequence alignment is as follows: HupZ 
locus tag: Spy_0844 [S. pyogenes M1 GAS]; IsdG locus tag: NWMN_1047 [S. aureus 
subsp. aureus str. Newman] ; IsdI locus tag: NWMN_0111 [S. aureus subsp. aureus str. 
Newman]; HugZ locus tag: HP0318 [H. pylori 26695]; HutZ locus tag: VCA0907 [V. 
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cholerae O1 biovar El Tor str. N16961]; PigA (Pa-HO) locus tag: PA0672 [P. 
aeruginosa PAO1]; HmuO locus tag: CDC7B_1652 [C. diphtheriae C7(beta)] ; HO-1 
locus tag: CTA-286B10.6 [Homo sapiens]; MhuD locus tag: Rv3592 [M. tuberculosis 
H37Rv]; HemS accession number: P31517 [Y. enterocolitica]; ChuS locus tag: 
E2348C_3742 [E. coli O127:H6 str. E2348/69]; PhuS accession number: AF055999 [P. 
aeruginosa PAO1]. Bootstrap units were obtained from 500 repeats of neighbor joining 
using the MEGA win-5.21 software.   
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FIGURE 13 
 
Figure 13: Heme exposure leads to lipid peroxidation in GAS. A. Cell growth. 
MGAS5005 cells growing in C-medium were treated with 4 μM heme in 0.035% DMSO 
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(Heme) or with mock treatment (0.035% DMSO, Control) at the early logarithmic growth 
phase. Culture samples were harvested 30, 60 and 90 min post exposure and processed. 
B. Malondialdehyde (MDA) standard curve. 100 l samples of MDA at a concentration 
of 0, 12.5, 25, 50, and 100 nmol/ml were allowed to react with thiobarbituric acid (TBA, 
see material and methods). The absorption at 532 nm of the supernatants from processed 
samples was determined and plotted as a function of MDA concentration exposure. The 
linear equation obtained for the standard curve was y = 0.0059x with R2 value of 0.9997. 
C. Lipid peroxidation following heme exposure. Cell lysates were prepared and allowed 
to react with TBA. The sample absorption at 532 nm was determined and the formation 
of TBA-reactive-substances (TBARS) was calculated using the standard curve shown in 
B. All samples were standardized with respect to the cell number in the corresponding 
culture. Data are representative of biological triplicates. 
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FIGURE 14. 
 
 
Figure 14: Protein oxidation following heme exposure. 
The membrane (A) and cytoplasmic proteins (B) extracted from cells harvested at 
different time points post treatment were allowed to react with DNPH (see material and 
methods) before fractionation by SDS-PAGE. Sample identity (H for heme treated cells 
and C for controls) and collection times (30, 60 and 90 min) are indicated [top panel]. 
Western blot with anti-DNP antibodies (OxyBlot) developed by chemiluminescence 
[bottom panel]. Coomassie blue-stained gel. All samples were standardized with respect 
to the cell number in the corresponding culture. C. Quantification of protein oxidation. 
The reaction with anti-DNP antibody in each membrane sample was quantified by 
densitometry. Arbitrary values for the heme treated samples (Heme) and mock treated 
(Control) after background subtraction are plotted. Error bars are shown. Data are 
representative of biological triplicates. Note that the western blot showing larger spots in 
an area outside of the lane is a technical artifact associated with the film development and 
it’s not a true reaction (prominent in Figure 9B, top panel). 
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FIGURE 15. 
 
  
Figure 15: GAS employs an adaptation strategy to avert growth phenotypes 
associated with heme stress. NZ131 cells were grown overnight in C-medium 
supplemented with 0.1 μM (adapted culture) and without heme (non-adapted culture). 
The overnight cultures were used as an inoculum to monitor growth in presence and 
absence of heme. Briefly, non-adapted culture was grown in C-media supplemented with 
0 and 1 μM heme, whereas adapted culture was sub-cultured into C-media containing 0.1 
and 1 μM heme. The growth was monitored colorimetrically for 8 hours at 37 °C. 
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FIGURE 16A 
 
 
Figure 16 A: Genes responding to heme stress in M1T1 GAS strain MGAS5005. 
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FIGURE 16 B 
 
 
Figure 11 B Genes responding to heme stress in M1T1 GAS strain MGAS5005. 
 
Total RNA was extracted 90 min post treatment and analyzed by microarray. A. Genes 
repressed or activated following exposure to 4 μM heme (in 0.035% DMSO) compared 
with mock treatment (0.035% DMSO). Data for genes whose expression was 
significantly different between cells exposed to heme and those subjected to mock 
treatment were combined and assigned to categories. B. Selected heme-activated genes 
revealing protein and redox stress response. Values represent relative expression levels 
(fold-change) in heme treated bacteria compare with mock treatment.    
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FIGURE 17. 
 
 
Figure 17: Multiple sequence alignment of PefR amino acid sequence from GBS and 
GAS. The degree of homology between GAS PefR (encoded by MGAS5005 spy_0195) 
and GBS PefR (encoded by gbs1402) is depicted in pair-wise sequence alignment 
performed using ClustalW. The amino acids are represented by single letter code. The 
symbols: (*) indicate identical residues; (:) indicate strongly similar residues; (.) 
designate weakly similar residues. An accuracy of alignment was also confirmed using 
MUSCLE tool (275) that showed identical alignment output as well. 
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FIGURE 18. 
 
 
Figure 18: The streptococcal pefRCD locus. A. Genetic organization of the pefRCD 
gene cluster in GAS. The putative PefR binding identified in silico and its homology to 
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the PefR binding motif from GBS (95) are shown.  B. Time course of pefRC expression 
in response to heme stress. Total RNA was extracted at different time points following 
heme or mock treatment and the relative expression of the pefR and pefC genes was 
evaluated by Real-time quantitative RT-PCR.  
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FIGURE 19. 
 
 
 
Figure 19: The PefR from GAS is a heme binding protein. A. A Coomassie blue-
stained gel showing purified recombinant PefR from GAS next to a molecular marker. B. 
Heme titration of PefR. UV-visible spectrum of 10 M PefR (in SPB) following 
incubation with an increasing concentration of hemin chloride (2-30 M) in 2 M 
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increments. SBP with the corresponding heme concentration was used as blank and 
subtracted from the sample spectrum. Heme binding by PefR is indicated by the 
increased absorption at 435, 530 and 560 nm. The arrow indicates the direction of the 
absorption changes. The images are of PefR as-purified from E. coli and of holo-PefR 
(after heme reconstitution and removal of heme excess by gel filtration and dialysis). This 
data represents three independent heme-titration experiments. C. Stoichiometry of heme 
binding to PefR. The changes in absorbance at 435 nm were plotted against heme 
concentration. The Kd was determined by fitting the data into modified hills equation for 
multiple binding sites (215). The Kd equals 10 M and nH (hill’s coefficient) is 1.37 M. 
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FIGURE 20. 
 
 
Figure 20: The PefR is capable of PPIX binding. A. PPIX titration of PefR. Change in 
the UV-visible spectral profile of 5 M of PefR (in SPB) when titrated with an increasing 
concentration of PPIX (0.25-6 M) in 0.5   increments was monitored across 
wavelength (300 – 700 nm). Free PPIX spectrum (shown in black) showed absorbance 
peaks in 432, 521, 556, 596, 655 and 685 nm regions. The PefR bound PPIX 
demonstrated maximum absorbance at 437 and 686 nm; absorbance at these wavelengths 
showed increase with PPIX concentrations (0.25 - 6 M; shown in different colors). The 
arrow indicates the direction of the absorption changes. B. Stoichiometry of PPIX 
binding to PefR. The spectral changes at 437 nm were plotted against PPIX 
concentration. The Kd was determined by fitting the data into linear equation.  
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FIGURE 21. 
 
 
 
Figure 21: The prevalence of the pefRCD operon in human and zoonotic 
streptococci. A. The genomic arrangement and occurrence of the pefRCD genes in GAS 
(MGAS5005 strain) and GBS (NEM316 strain) is also conserved among members of the 
pyogenic cluster namely, S. equi (4047 strain), S. uberis (0140J strain), and S. iniae 
(ISET0901). Additionally, this system is found in S. suis (JS14 strain). These PefCD 
homologs are referred to as SatAB in the literature (255). The pef operon consists of a 
MarR-like transcriptional regulator (locus tag for strains tested: Spy_0195, gbs1402, 
SEQ_0290, SUB_1690, SSUJS14_1996, and DQ08_09375) controlling an adjacent ABC-
type efflux system (Spy_0196-97, gbs1401-00, SEQ_0292-93, SUB_1689-88, 
SSUJS14_1995-94, and DQ08_09370-65). The neighboring genes upstream and 
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downstream from the pef operon consist of lipid metabolism (gpsA) and unknown 
functions, respectively. B. The efflux system, PefCD belongs to the class-1 type of ABC 
transporters. PefC and PefD both contain a membrane permease domain fused to an 
ATPase domain on the same polypeptide chain.  
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FIGURE 22. 
 
 
 
 
Figure 22: Insertional inactivation of pefC in GAS leads to impaired growth 
phenotype. A. A schematic representation of the pefC::pMZ1 mutation in the ZE4951 
strain and the plasmids used for complementation analysis. The aad9 and aphA3 genes 
confer the resistance to spectinomycin (SpecR) and kanamycin (KanR), respectively. MCS 
is a multiple cloning site. The Ori (pSH71 derivative) enabled replication of plasmids in 
multiple hosts (E. coli and GAS). Plasmid pANKITA5b carries the pefRCD cluster 
cloned into the MCS in pKSM201. B. Growth of the NZ131 (WT), ZE4951 (Mutant), 
ZE4951/pANKITA5b (Complement), and ZE4951/pKSM201 (Empty vector) strains. 
Fresh THYB media were inoculated with GAS cells (OD600 nm = 0.05) and the cultures 
were grown statically at 37 °C. Cell growth was monitored colorimetrically and 
expressed in Klett units. The data are representative of two independent experiments.  
  
 
144 
FIGURE 23. 
 
 
 
Figure 23: The PefCD transporter protects GAS from heme-mediated lipid 
oxidation. A. Lipid peroxidation standard curve. The curve was generated by plotting the 
absorbance monitored at 532 nm and formed as a result of reactivity between a series of 
malondialdehyde solutions (0, 12.5, 25, 50, and 100 nmol/ml) with the TBA reagent. B. 
Lipid peroxidation following heme exposure. Cultures of NZ131 (WT), ZE4951 
(Mutant), ZE4951/pANKITA5b (Complement), and ZE4951/pKSM201 (Empty vector) 
strains were treated with 1 μM heme during the mid logarithmic phase of growth (60-70 
Klett units). Culture samples were then collected at 30, 60, and 90 min post-heme 
exposure and allowed to react with TBA. The sample absorption at 532 nm was 
determined, and the formation of TBA-reactive-substances (TBARS) was calculated 
using the standard curve shown in A. All samples were standardized with respect to cell 
number. The data are derived from two independent experiments, each performed in 
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triplicates. The asterisk (*) denotes that the observed P value is statistically significant (P 
< 0.05) calculated using student t-test (equal variance) at 0.05 levels of significance.  
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FIGURE 24. 
  
 
 
 
Figure 24: The PefCD transporter protects GAS chromosome from heme-mediated 
GAS damage. A. AP sites standard curve. The curve was generated by plotting 
absorbance at 650 nm from a genomic DNA series with 0, 8, 16, 24, 32, and 40 AP sites / 
105 bp after reaction with the ARP probe. B. AP site formation in GAS chromosome 
following heme exposure. Cultures of NZ131 (WT), ZE4951 (Mutant), 
ZE4951/pANKITA5b (Complement), and ZE4951/pKSM201 (Empty vector) strains 
were treated with 5 μM heme during the mid logarithmic phase of growth (60-70 Klett 
units). Genomic DNA was extracted from samples collected at 0, 30 and 90 min post 
exposure was allowed to react with ARP-biotin and analyzed. The sample absorption at 
650 nm was determined and AP site formation was calculated using the standard curve 
shown in A. All samples were standardized with respect to cell number. The data are 
derived from two independent experiments each done in triplicates. The asterisk (*) 
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denotes that the observed P value is statistically significant (P < 0.05) and is calculated 
using student t-test (equal variance) at 0.05 levels of significance.  
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FIGURE 25. 
 
 
 
 
Figure 25: Inactivation of the pefCD transporter leads to cellular accumulation of 
heme in cells grown in the presence of heme. A. UV-visible spectra across wavelengths 
(250-700 nm) were recorded for organic fractions recovered after acidified chloroform 
extraction performed on a range of hemin chloride standards. B. The observed 
absorbance at 388, 450, and 330 nms from UV scans (of organic fractions) were plugged 
into Ac = 2A388 − (A450 + A330) equation. The Ac values for standards extracted using 
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chloroform for a range of hemin concentrations (0-4 μM, with 0.5 μM increments) were 
plotted against its hemin concentrations to generate a standard plot. The line equation of a 
standard plot was used to extrapolate hemin concentrations in the experimental samples. 
Cultures of NZ131 (WT), ZE4951 (Mutant), ZE4951/pANKITA5b (Complement), and 
ZE4951/pKSM201 (Empty vector) strains were treated with 3 μM heme during the mid 
logarithmic phase of growth (60-70 Klett units). Cells were harvested, washed, and were 
subjected to chloroform extraction. C. UV-visible spectra across different wavelengths 
(250-700 nm) of the collected organic phases from tests samples were recorded. D. Heme 
concentration in the test samples. The concentrations of heme in the test samples were 
calculated using the standard curve shown in B. The data are derived from two 
independent experiments each performed in triplicates. The asterisk (*) denotes that the 
observed P value is statistically significant (P < 0.05) calculated using student t-test 
(equal variance) at 0.05 levels of significance.  
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FIGURE 26. 
 
 
 
 
Figure 26: A schematic depiction of heme-tolerance transporters described in 
streptococci. 
Putative homologs of the HrtAB (Class-3 ABC-type transporter) were identified in GBS, 
and were shown to be induced by heme. The PefAB and PefCD are heme and PPIX 
efflux machineries used by GBS. PefAB is related to the drug/proton antiporter family, 
while PefCD consists of Class-1 ABC type transporter. Our data show that GAS employs 
PefCD to efflux heme and provide cyto-protective function to various biomolecules. 
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Appendix C: Supplementary Tables 
Table 1: The S. pyogenes MGAS5005 Heme stimulon. 
 
 Locusa Geneb Expressionc Putative functiond 
Activated in the presence of Heme  
 Spy0013 ftsH 
2.182 ± 
0.033 Cell division protein - COG0465 [O] 
 Spy0031 purK 2.01 ± 0.095 
Phosphoribosylaminoimidazole carboxylase 
ATPase subunit - COG0026 [F] 
 Spy0157 opuAA 
2.638 ± 
0.162 
GB transport ATP-binding protein - 
COG4175 [E] 
 Spy0158 opuABC 
2.127 ± 
0.147 
GB-binding protein/GB transport system 
permease protein - COG2113/4176 [E] 
 Spy0186  
2.552 ± 
0.086 Transcriptional regulator - COG1846 [K] 
 Spy0195 pefR 
2.778 ± 
0.101* 
Transcriptional regulator, MarR family - 
COG1846 [K] 
 Spy0196 pefC 
2.001 ± 
0.104 
MDR ABC transporter ATP-binding and 
permease protein - COG1132 [V] 
 Spy0197 pefD 
2.112 ± 
0.086 
MDR ABC transporter ATP-binding and 
permease protein - COG1132 [V] 
 Spy0275  
2.673 ± 
0.112 
Serine/threonine sodium symporter - 
COG3633 [E] 
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 Spy0300  
3.594  ± 
0.091 Hydrolase, HAD superfamily - COG1418 [R] 
 Spy0301  4.24 ± 0.103 Integral membrane protein - COG0670 [R] 
 Spy0328 clpP 
2.191 ± 
0.061 
ATP-dependent Clp protease proteolytic 
subunit - COG0740 [O] 
 Spy0329  
2.036 ± 
0.127 Hypothetical cytosolic protein 
 Spy0382 msrA.2 
2.202 ± 
0.108 
Peptide methionine sulfoxide reductase - 
COG0225 [O] 
 Spy0383  
2.539 ± 
0.109 D-alanyl-D-alanine carboxypeptidase 
 Spy0385  
2.609 ± 
0.088 
67 kDa Myosin-crossreactive antigen - 
COG0493 [E] 
 Spy0423 pepQ 
2.162 ± 
0.074 Xaa-Pro dipeptidase - COG0006 [E] 
 Spy0425  2.235 ± 0.07 Glycosyltransferase - COG0438 [M] 
 Spy0456  
2.519 ± 
0.122 
Plasmid stabilization system antitoxin protein 
- COG3077 [L] 
 Spy0457  
2.185 ± 
0.101 
Plasmid stabilization system protein - 
COG2026 [J/D] 
 Spy0474 licT 
2.406 ± 
0.099 
Transcription antiterminator, BglG family - 
COG3711 [K] 
 Spy0477  2.195 ± Hypothetical membrane spanning protein - 
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0.061 COG3689 [S] 
 Spy0479  
2.804 ± 
0.078 
Hypothetical membrane spanning protein - 
COG0785 [O] 
 Spy0483  
4.014 ± 
0.105 
Stress-responsive transcriptional regulator - 
COG1983 [K/T] 
 Spy0509 tpi 
3.168 ± 
0.075 Triosephosphate isomerase - COG0149 [G] 
 Spy0534  
2.219 ± 
0.102 
(R,R)-butanediol dehydrogenase/acetoin 
dehydrogenase - COG1028 [I/Q/R] 
 Spy0660 fruR 
3.791 ± 
0.165 Fructose repressor - COG1349 [K/G] 
 Spy0661 fruB 
4.285 ± 
0.163 1-phosphofructokinase - COG1105 [G] 
 Spy0662 fruA 
2.774 ± 
0.153 
PTS system, fructose-specific IIABC 
component - COG1299/1445/1762 [G/T] 
 Spy0677 fms 
2.111 ± 
0.073 Peptide deformylase - COG0242 [J] 
 Spy0694 clpL 
3.928 ± 
0.141 
Putative ATP-dependent Clp proteinase 
(ATP-binding subunit) - COG0542 [O] 
 Spy0743  
3.181 ± 
0.139 
ABC transporter substrate-binding protein - 
COG2984 [R] 
 Spy0744  
2.488 ± 
0.113 Hypothetical protein 
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 Spy0745  
2.051 ± 
0.147 
ABC transporter permease protein - 
COG4120 [R] 
 Spy0877  
2.511 ± 
0.082 Hypothetical protein 
 Spy0878  
2.527 ± 
0.104 Hypothetical protein 
 Spy0880 hlyIII 
2.092 ± 
0.123 Putative hemolysin III - COG1272 [R] 
 Spy0910 citC 
2.009 ± 
0.058 
(Citrate [pro-3S]-lyase)-ligase - COG3053 
[C] 
 Spy0924  
2.105 ± 
0.131 Transcriptional regulator, GntR family 
 Spy0947 ciaH 
2.353 ± 
0.055 TCS histidine kinase - COG1167 [K/E] 
 Spy0948 ciaR 
2.094 ± 
0.057 TCS response regulator - COG074 [T/K] 
 Spy0982  
2.188 ± 
0.089 Histidine-binding protein - COG0834 [E/T] 
 Spy1137 coiA 2.296 ± 0.12 
Putative competence protein/transcription 
factor 
 Spy1138 rsuA 2.823 ±0.136 
Ribosomal small subunit pseudouridine 
synthase A - COG1187 [J] 
 Spy1139 nagB 3.114 ± Glucosamine-6-phosphate isomerase - 
  
 
155 
0.132 COG0363 [G] 
 Spy1203  
2.074 ± 
0.027 Phage protein 
 Spy1222 int.2 1.94 ± 0.143 Phi5005.2 integrase - COG0582 [L] 
 Spy1240 clpE 
5.047 ± 
0.174 
ATP-dependent clp protease ATP-binding 
subunit - COG0542 [O] 
 Spy1345 atoD.1 
2.115 ± 
0.122 
Acetate CoA-transferase alpha subunit - 
COG1788 [I] 
 Spy1406 copY 
2.109 ± 
0.102 
CopAB ATPases metal-fist type repressor - 
COG3682 [K] 
 Spy1477  2.34 ± 0.117 
Guanine-hypoxanthine permease - COG2252 
[R] 
 Spy1497 dnaJ 
3.327 ± 
0.103 Chaperone protein - COG0484 [O] 
 Spy1498 dnaK 4.58 ± 0.09 Chaperone protein - COG0443 [O] 
 Spy1499 grpE 
3.876 ± 
0.112 Hypothetical protein - COG0576 [O] 
 Spy1500 hrcA 
4.081 ± 
0.142 
Heat-inducible transcription repressor - 
COG1420 [K] 
 Spy1559 trx 
2.491 ± 
0.125 Thioredoxin - COG0526 [O/C] 
 Spy1633 lacE 
2.127 ± 
0.066 
PTS system, lactose-specific IIBC component 
- COG1455 [G] 
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 Spy1669 def 
1.991 ± 
0.091 Peptide deformylase - COG0242 [J] 
 Spy1670  
2.936 ± 
0.101 Oxidoreductase - COG0431 [R] 
 Spy1709  2.961 ± 0.17 Hypothetical protein - COG3237 [S] 
 Spy1722  
2.448 ± 
0.082 
Hypothetical protein (Mga-associated) - 
COG0477 [G/E/P/R ] 
 Spy1723 isp 
2.585 ± 
0.131 
Immunogenic secreted protein - COG0810 
[M] 
 Spy1724 ihk 
2.554 ± 
0.136 TCS histidine kinase - COG0642 [T] 
 Spy1725 irr 
2.719 ± 
0.164 TCS response regulator - COG0745 [T/K] 
 Spy1727  
3.699 ± 
0.118 
ABC transporter ATP-binding protein - 
COG1136 [V] 
 Spy1728  
2.458 ± 
0.127 
Periplasmic component of efflux system - 
COG0845 [M] 
 Spy1729  
3.357 ± 
0.148 Hypothetical protein 
 Spy1730  
2.691 ± 
0.078 Hypothetical protein 
 Spy1732 prsA 8.63 ± 0.043 
Protein export protein PrsA precursor - 
COG0760 [O] 
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 Spy1753  pbp2A 
2.173 ± 
0.036 
Multimodular transpeptidase-transglycosylase 
- COG074 [M] 
 Spy1761 groEL 
8.351 ± 
0.134 60 kDa chaperonin - COG0459 [O] 
 Spy1762 groES 
7.951 ± 
0.134 10 kDa chaperonin - COG0234 [O] 
 Spy1763 clpC 
2.576 ± 
0.075 
Negative regulator of genetic competence - 
COG0542 [O] 
 Spy1764 ctsR 
2.567 ± 
0.124 Transcriptional regulator 
 Spy1798 spxA2 
5.238 ± 
0.093 
suppressor of clpP & clpX, spxA2 allele - 
COG1393 [P] 
 Spy1853 hasC 
2.204 ± 
0.078 
UTP--glucose-1-phosphate uridylyltransferase 
- COG1210 [M] 
 Spy1865 htrA 3.539 ± 0.12 Protease Do - COG0265 [O] 
Repressed in the presence of Heme  
 Spy0015  0.43 ± 0.158 Hypothetical protein 
 Spy0040 adhA 
0.368 ± 
0.112 Alcohol dehydrogenase - COG1064 [R] 
 Spy0117  
0.333 ± 
0.088 
Transcriptional regulator, LysR family - 
COG0583 [K] 
 Spy0118  0.374 ± 0.09 
Transcriptional regulator, LysR family - 
COG0583 [K] 
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 Spy0127 ntpK 
0.246 ± 
0.275 
V-type sodium ATP synthase subunit K - 
COG0636 [C] 
 Spy0129 ntpC 
0.219 ± 
0.274 
V-type ATP synthase subunit C - COG1527 
[C] 
 Spy0130 ntpF 
0.219 ± 
0.258 
V-type sodium ATP synthase subunit F - 
COG1436 [C] 
 Spy0131 ntpA 
0.118 ± 
0.306 
V-type sodium ATP synthase subunit A - 
COG1155 [C] 
 Spy0132 ntpB 0.092 ± 0.35 
V-type sodium ATP synthase subunit B - 
COG1156 [C] 
 Spy0133 ntpD 
0.138 ± 
0.328 
V-type sodium ATP synthase subunit D - 
COG1394 [C] 
 Spy0340 lctO 
0.249 ± 
0.124 L-lactate oxidase - COG1304 [C] 
 Spy0361  
0.458 ± 
0.107 
Phosphoglycerate transporter protein - 
COG2271 [G] 
 Spy0562 sagA 0.31 ± 0.19 Streptolysin S biosynthesis protein 
 Spy0563 sagB 
0.325 ± 
0.124 
Streptolysin S biosynthesis protein - 
COG0778 [C] 
 Spy0564 sagC 
0.334 ± 
0.116 Streptolysin S biosynthesis protein 
 Spy0565 sagD 
0.286 ± 
0.129 Streptolysin S biosynthesis protein 
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 Spy0566 sagE 
0.329 ± 
0.105 
Streptolysin S putative self-immunity protein 
- COG1266  [R] 
 Spy0567 sagF 
0.273 ± 
0.135 
Streptolysin S biosynthesis protein - 
COG0477 [G/E/P/R] 
 Spy0568 sagG 
0.282 ± 
0.127 
Streptolysin S export ATP-binding protein - 
COG1131 [V] 
 Spy0569 sagH 
0.304 ± 
0.146 
Streptolysin S export transmembrane protein - 
COG0842 [V] 
 Spy0570 sagI 
0.354 ± 
0.113 
Streptolysin S export transmembrane protein - 
COG0842 [V] 
 Spy0571  
0.312 ± 
0.086 
Endonuclease/exonuclease/phosphatase 
family protein - COG2374 [R] 
 Spy0780 ptsA 
0.069 ± 
0.312 
PTS system, mannose/fructose family IIA 
component - COG2893 [G] 
 Spy0781 ptsB 
0.073 ± 
0.298 
PTS system, mannose/fructose family IIB 
component - COG3444 [G] 
 Spy0782 ptsC 
0.093 ± 
0.262 
PTS system, mannose/fructose family IIC 
component - COG3715 [G] 
 Spy0783 ptsD 
0.369 ± 
0.202 
PTS system, mannose/fructose family IID 
component - COG3716 [G] 
 Spy0784 spt5S 
0.467 ± 
0.112 TCS histidine kinase - COG2972 [T] 
 Spy0830 dpiA 0.419 ± Transcriptional regulatory protein - COG4565 
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0.129 [K/T] 
 Spy0901  
0.273 ± 
0.174 Hypothetical protein 
 Spy0905 citD 
0.306 ± 
0.183 
Citrate lyase acyl carrier protein - COG3052 
[C] 
 Spy0906 citE 
0.291 ± 
0.169 
Citrate lyase beta chain/citryl-CoA lyase 
subunit - COG2301 [G] 
 Spy0907 citF 0.33 ± 0.129 
Citrate lyase alpha chain/citrate CoA-
transferase - COG3051 [C] 
 Spy0908 citX 
0.315 ± 
0.107 
Apo-citrate lyase phosphoribosyl-dephospho-
CoA transferase - COG3697 [H/I] 
 Spy0929  
0.479 ± 
0.089 SIR2 family protein - COG0846 [K/E] 
 Spy0930  
0.428 ± 
0.103 
ATPase associated with chromosome 
architecture/replication - COG2110 [R] 
 Spy0931  0.411 ± 0.1 
Glycine cleavage system H protein - 
COG0509 [E] 
 Spy0932  
0.416 ± 
0.102 
Luciferase-like monooxygenase - COG2141 
[C] 
 Spy0933  
0.428 ± 
0.085 
Probable NADH-dependent flavin 
oxidoreductase - COG1902 [C] 
 Spy0940  0.48 ± 0.059 
Nucleoside transport system permease protein 
- COG4603 [R] 
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 Spy0941  
0.417 ± 
0.067 
Nucleoside transport ATP-binding protein - 
COG3845 [R] 
 Spy0942  
0.459 ± 
0.079 Nucleoside-binding protein - COG1744 [R] 
 Spy0944  
0.443 ± 
0.074 
16S rRNA m(2)G 1207 methyltransferase - 
COG2813 [J] 
 Spy0951 pstB 
0.491 ± 
0.046 
Phosphate transport ATP-binding protein - 
COG1117 [P] 
 Spy1058 malE 
0.373 ± 
0.135 
Maltose/maltodextrin-binding protein - 
COG2182 [G] 
 Spy1076 glnH 
0.422 ± 
0.047 Transporter - COG0765 [E/T ] 
 Spy1084  
0.468 ± 
0.118 Outer surface protein - COG3589 [S] 
 Spy1161  0.346 ± 0.12 Formate transporter - COG2116 [P] 
 Spy1270 arcC 
0.283 ± 
0.152 Carbamate kinase - COG0549 [E] 
 Spy1271  
0.278 ± 
0.104 Xaa-His dipeptidase - COG0624 [E] 
 Spy1272  
0.315 ± 
0.125 Arginine/ornithine antiporter - COG1288 [S] 
 Spy1273 arcB 
0.402 ± 
0.091 
Ornithine carbamoyltransferase - COG0078 
[E] 
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 Spy1286  
0.483 ± 
0.056 DNA polymerase - COG1518 [L] 
 Spy1303 aroE 
0.461 ± 
0.149 Shikimate 5-dehydrogenase - COG0169 [E] 
 Spy1304 lacZ 
0.306 ± 
0.174 Beta-galactosidase - COG3250 [G] 
 Spy1305 trxR 
0.243 ± 
0.158 TCS response regulator - COG4753 [T] 
 Spy1306 trxS 
0.345 ± 
0.162 TCS histidine kinase - COG2972 [T] 
 Spy1307  0.22 ± 0.145 Hypothetical membrane spanning protein 
 Spy1308  
0.168 ± 
0.201* Sugar-binding protein - COG1653 [G] 
 Spy1309  0.137 ± 0.18 
Sugar transport system permease protein - 
COG0395 [G] 
 Spy1310  
0.184 ± 
0.146 
Sugar transport system permease protein - 
COG4209 [G] 
 Spy1315  
0.454 ± 
0.053 
Transcriptional regulator, GntR family - 
COG1609 [K] 
 Spy1316  
0.459 ± 
0.082 Hypothetical protein - COG3538 [S] 
 Spy1376  
0.234 ± 
0.182 Transaldolase - COG0176 [G] 
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 Spy1377  
0.239 ± 
0.136 trans-acting positive regulator 
 Spy1378  
0.322 ± 
0.099 NADH peroxidase - COG0446  [R] 
 Spy1379 glpF 
0.209 ± 
0.184 
Glycerol uptake facilitator protein - COG0580 
[G] 
 Spy1380 glpO 
0.181 ± 
0.133 
Alpha-glycerophosphate oxidase - COG0578 
[C] 
 Spy1381 glpK 
0.085 ± 
0.255 Glycerol kinase - COG0554 [C] 
 Spy1539 scrK 0.32 ± 0.088 Fructokinase - COG1940 [K] 
 Spy1540 endoS 
0.176 ± 
0.105 
Endo-beta-N-acetylglucosaminidase F2 
precursor 
 Spy1596 glnA 
0.409 ± 
0.112 Glutamine synthetase - COG0174 [E] 
 Spy1597 glnR 
0.389 ± 
0.078 
Transcriptional regulator, MerR family - 
COG0789 [K] 
 Spy1682 msmK 
0.392 ± 
0.131 
Multiple sugar transport ATP-binding protein 
- COG3839 [G] 
 Spy1758  0.5 ± 0.099 Probable dipeptidase B - COG4690 [E] 
 Spy1771 hutU 
0.242 ± 
0.146 Urocanate hydratase - COG2987 [E] 
 Spy1772  0.22 ± 0.192 Glutamate formiminotransferase - COG3643 
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[E] 
 Spy1773  0.16 ± 0.178 
Formiminotetrahydrofolate cyclodeaminase - 
COG3404 [E] 
 Spy1774 fhs.2 
0.136 ± 
0.138 
Formate--tetrahydrofolate ligase - COG2759 
[F] 
 Spy1775  0.15 ± 0.16 Hypothetical cytosolic protein - COG3758 [S] 
  Spy1776   
0.154 ± 
0.182 Amino acid permease - COG0531 [E] 
 
aSpy numbers from MGAS5005 genome. 
bWhen available, gene name is provided. 
cArray mean ± standard error. Numbers with an asterisk represent the average of array 
means obtained from 2 or more distinct probes for the same locus. 
dPutative function using nomenclature from the J. Craig Venter Institute (JCVI) CMR 
database. ABC, ATP-binding cassette; CoA, coenzyme A; GB, Glycine betaine; MDR, 
multiple drug resistance; PTS, PEP-dependant phosphotransferase system; TCS, two-
component system. Further information relative to the gene-encoded protein is provided 
using the NCBI Clusters of Orthologous Groups (COG) database. Function categories are 
given using the letter-based nomenclature from the COG database. Information storage 
and processing: J, translation, ribosomal struture and biogenesis; A, RNA processing and 
modification; K, transcription; L, replication, recombinaison and repair; B, chromatin 
structure and dynamics. Cellular processes and signaling: D, cell cycle control, cell 
division, chromosome partitioning; Y, nuclear structure; V, defense mechanisms; T, 
signal transduction mechanisms; M, cell wall/membrane/envelope biogenesis; N, cell 
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motility; Z, cytoskeleton; W, extracellular structures; U, intracellular trafficking, 
secretion, and vesicular transport; O, posttranslational modification, protein turnover, 
chaperones. Metabolism: C, energy production and conversion; G, carbohydrate transport 
and metabolism; E, amino acid transport and metabolism; F, nucleotide transport and 
metabolism; H, coenzyme transport and metabolism; I, lipid transport and metabolism; P, 
inorganic ion transport and metabolism; Q, secondary metabolites biosynthesis, transport 
and catabolism. Poorly characterized: R, general function prediction only; S, unknown 
function. 
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Appendix D: Supplementary Figures 
 
 
 Figure 1: Microarray data validation. 
 
A. A set of 11 genes representing the range of possible changes, i.e. increase (prsA, clpL, 
opuAA), decrease (endoS, ptsA, sagA, spt7R) and no effect (slo, fasC, mtsA) were selected 
and their expression analyzed by real-time RT-PCR. B. Plotting the log value of the array 
on the x-axis against the log value of the real-time RT-PCR on the y-axis revealed strong 
correlation (calculated R2 = 0.892) between the two datasets. 
 
